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INTRODUCTION 
Throughout the ages humans have entrusted on Nature to cater for their basic needs, not 
the least of which are medicines for the treatment of a wide spectrum of diseases. 
Plants, in particular, have formed the basis of refined traditional medicine systems, with 
the earliest records, dating from around 2600 BCE, documenting the uses of 
approximately 1000 plant-derived substances in Mesopotamia [1]. The World Health 
Organization (WHO) had already estimated in 1985 that approximately 65% of the 
population of the world predominately relied on plant-derived traditional medicines for 
their basic health care, while plant products also play an important, though more 
indirect role in the health care systems of the remaining population who mainly reside 
in developed countries. A research of plant-derived pure compounds used as drugs in 
countries hosting WHO-Traditional Medicine Centers indicated that, of 122 compounds 
recognized, 80% were used for the same or correlated ethnomedical purposes and were 
derived from only 94 plant species [2].  
Some relevant examples show how molecules that have been discovered from natural 
plant source can treat various aspects relating to human health care, in particular : 
galegine, from Galega officinalis L., which was the model for the synthesis of 
metformin and other bisguanidine-type antidiabetic drugs; ephedrine, from Ephedra 
sinica, a plant long used in traditional Chinese medicine, and the basis for the synthesis 
of the anti-asthma agents (beta agonists) like salbutamol and salmetrol; quinine, from 
the bark of Cinchona species (e. g., C. officinalis), that formed the basis for the 
synthesis of the commonly used antimalarial drugs, chloroquine and mefloquine; 
vinblastine and vincristine, isolated from the Madagascar periwinkle, Catharanthus 
roseus, important plant-derived anticancer drugs in clinical use; galantamine, a natural 
product discovered through an ethnobotanical lead and first isolated from Galanthus 
woronowii Losinsk., to date used to treat symptoms due to Alzheimer's disease.  
The importance of natural products lies not only in their direct utilization, but also, in 
order to constitute the pharmacophore or synthons for new molecules, reason is that 
they often possess highly selective and specific biological activities based on 
mechanisms of action. From this perspective, the products arising from natural 
compounds or their direct modifications represent 50% of the new chemical entities 
(NCEs), as shown in Figure 1 [3].  
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Fig. 1 Cragg et al. (2013), sources of current drugs represented by pie chart  
an unmodified natural product 
a natural product botanical 
amodified natural product 
a synthetic compound with no natural product conception 
a synthetic compound showing competitive inhibition of the natural product substrate 
a synthetic compound with a natural product pharmacophore 
a synthetic compound with a natural product pharmacophore that showing 
competitive inhibition of the natural product substrate 
 
 
The activity of natural products is mainly related to secondary metabolites from plants, 
compounds that can be generally classified into [4]: 
 Phenols 
 Compounds Sulphur-Containing 
 Terpenes 
 Alkaloids 
Each group has different pharmacological activities, and can be divided into different 
classes according to own chemical structure. 
Phenols, through phenolic ring structure, can play directly activity in free radical 
scavenger, reducing agents, prooxidants metal chelating and quencher in formation of 
oxygen radicals. Preclinical studies have revealed that these compounds show important  
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protective activities against many pathological conditions, particularly where is 
involved a component of oxidative stress [5]. 
Compounds Sulphur-Containing, derived from two main sources in the diet: those 
derived from the glucosinolate–myrosinase (substrate–enzyme) system found in 
cruciferous crops, such as cabbages, broccoli (Brassica oleracea) and watercress 
(Nasturtium officinale), and those derived from the alliin-alliinase system found within 
Allium crops, such as garlic (A. sativum), onions (A. cepa) and leeks (A. porrum). At 
these molecules are due the flavor and aroma, as well as many of the alleged therapeutic 
effects associated with these plants, including the potential chemopreventive, anti-
thrombotic, hypoglycemic and hypolipidemic [6]. 
Terpenes represent one of the largest families of natural products, including more than 
40.000 compounds. Their most important structural property is the long series of 
conjugated double bonds in the central part of the molecule. This kind of structure 
makes the molecule vulnerable to oxidation and cis-trans isomerisation [7]. 
Alkaloids are heterogeneous group of low molecular weight, nitrogen-containing 
compounds mostly derived from amino-acids and found in about 20% of plant species. 
As secondary metabolites, alkaloids are considered to play a defensive role in the plant 
against herbivores and pathogens. Due to their potent biological activity, many of the 
approximately 12.000 known alkaloids have been exploited as pharmaceuticals, 
stimulants, narcotics and poisons [8]. 
Since has been said previously, plants play a key role in human health care. In the same 
way at the development of the research of novel natural compounds, has increased the 
demand for more and most easily available plant sources. At the UN (United Nations) 
Conference held in Rio de Janeiro in 1992, have been established parameters for the 
preservation of biological diversity by promoting sustainable use of sources, this 
involves the use of natural resources in ways and times that do not lead the depletion of 
biodiversity. For this reason in the last decade have been increasingly investigated 
methods for the development of in vitro plant cell cultures. Advances in biotechnology 
for culturing plant cell cultures, today allow to obtain secondary metabolites in large 
quantity, bypassing problem to impoverish endangered natural sources, and by using 
suitable elicitors, get a possibility to increase or select the secondary metabolites 
production.  
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According to what said above, in this work particular attention was given to the study of 
secondary metabolites produced by some plants belonging to the Amaryllidaceae 
family, in the specific case isoquinoline alkaloids.  
At the first instance were characterized both qualitatively and quantitatively three 
different plants belonging to Amaryllidaceae family, such as: Crinum angustum Steud., 
Pancratium illyricum L., and Leucojum nicaeense Ard. The alkaloids extracts obtained 
were separately tested against enzymes involved in specific diseases or liable in 
multifactorial pathologies. Considering the protection role against external bodies 
carried out by these metabolites in plant, extracts were also assayed against ATCC 
microorganisms and clinical isolates. Plants with promising pharmacological activities 
have been the basis for development of in vitro plant models. 
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CHAPTER 1 
PLANTS OF AMARYLLIDACEAE FAMILY 
1.1 INTRODUCTION 
The Amaryllidaceae are a family of monocotyledonous plants, represented by 59 genera 
and over 850 species all over the world [9], assigned by APG (Angiosperm Phylogeny 
Group III) classification to the order of Asparagales. These plants have mostly tropical 
and subtropical distribution and their presence in temperate areas is less significant. 
South America (28 genera) and South Africa (19 genera) are the regions with major 
diversity. The Mediterranean region, being the source of numerous horticultural 
introductions, has only eight genera, whereas Australia has only three genera. 
Amaryllidaceae plants occupy many different habitats: seasonally dry places, ephemeral 
pools, rainforests understory, and rivers. Currently, molecular evidence places the most 
ancient lineages and the origin of the family in Africa [10]. The family is essentially 
composed by bulbous plants that in temperate areas, in the winter season losing their 
entire epigeal portion stems and leaves, so as to disappear completely at the sight. 
Though several plants belonging to this family have a considerable size, indeed in some 
cases can exceed 2 meters high, in other instances are less than 10 centimeters tall. 
Having regard to the use made of these plants in the research of novel natural 
compounds, the urban areas development at the expense of natural one, and in some 
cases their limited size, to date most of the Amaryllidaceae plants family which grow in 
the Mediterranean area are endangered. 
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1.2 THE AMARYLLIDACEAE ALKALOIDS AND THEIR BIOLOGICAL 
ACTIVITIES 
A peculiar property of the Amaryllidaceae plants is a consistent presence of an 
exclusive group of alkaloids, which have been isolated from plants of all the genera of 
this family. In fact, the Amaryllidaceae alkaloids represent a large, and still expanding, 
group of isoquinoline alkaloids, the majority of which are not known to occur in any 
other family plants. Since the isolation of lycorine from Narcissus pseudonarcissus in 
1877, over 300 alkaloids have been isolated from plants of this family [11], and though 
their structures vary significantly, these alkaloids are considered to biogenetically 
related. The large number of structurally different Amaryllidaceae alkaloids are 
classified mainly into nine skeleton types as reported by the Ghosal’s model, for which 
the representative alkaloids are: norbelladine, lycorine, homolycorine, crinine, 
hemanthamine, narciclasine, tazetine, montanine and galanthamine (Fig 1.1). 
 
 
 
Fig. 1.1 Amaryllidaceae Alkaloid types 
 
Plants of the Amaryllidaceae family have been used for thousands of years as herbal 
remedies, and the alkaloids from their extracts have been the object of active chemical  
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investigation for nearly 200 years. Over the past two decades many have been isolated, 
and screened for different biological activities by a number of research groups. A 
relevant issue about these alkaloids is their availability, in fact are obtained only in 
small quantities from natural source. For this reason, is highly developed the practice of 
synthesize or semi synthesize these alkaloids and their derivatives [12].  
In spite of the great variety of pharmacological and biological properties exhibited by 
Amaryllidaceae alkaloids, only some of the activities of a reduced number of these 
molecules have been reported. The relationship of chemical structure and biological 
activity is largely unknown, and further studies are needed to explore the full 
therapeutic potential of these alkaloids. 
Generally, activity displayed by the Amaryllidaceae alkaloids can be traced to principal 
groups to which they belonging: 
 Lycorine types, with lycorine, their most representative and characteristic 
Amaryllidaceae alkaloids, have been reported to be strong inhibitors on parasite 
development and antifungal activity [13]. Additionally, the alkaloids of lycorine 
types are potent inducers of apoptosis in human leukemia cells, are selective 
inhibitors of human ovarian cancer cell, and may exert antiviral effects on 
several RNA- and DNA-containing viruses [14]. 
 Homolycorine types, some alkaloids of this series, such as homolycorine, being 
moderately active in inhibiting the in vivo and in vitro growth of a variety of 
tumor cells, such as Molt 4 lymphoma, HepG2 human hepatoma, and LNCaP 
human prostate cancer [15]. Other alkaloids homolycorine types show DNA 
binding activity comparable to that vinblastine [16]. 
 Hemanthamine types and Crinine types, display pronounced cell growth 
inhibitory activities against a variety of tumor cells, such as Rauscher viral 
leukemia, Molt 4 lymphoma, BL6 mouse melanoma, HepG2 human hepatoma, 
HeLa, LNCaP human prostate cancer [17]. Vittatine, as reported in Evidente et 
al. (2004) an alkaloids of this group, has antibacterial activity against the Gram-
positive Staphylococcus aureus and Gram-negative E. coli. 
 Tazettine types, displays weak hypotensive and antimalarial activities and 
interacts with DNA. Pretazettine, alkaloids of this group and labile precursor of  
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tazettine, shows cytotoxicity against fibroblastic LMTK cell lines and inhibits 
HeLa cell growth, being therapeutically effective against advanced Rauscher  
leukemia, Ehrlich ascites carcinoma, spontaneous AKR lymphocytic leukemia, 
and Lewis lung carcinoma. It is one of the most active of the Amaryllidaceae 
alkaloids against Molt 4 lymphoid cells [18] [19]. 
 Narciclasine types, are an antimitotic and antitumoral alkaloids, affects cell 
division at the metaphase stage and inhibits protein synthesis in eukaryotic 
ribosomes by directly interacting with the 60S subunit [20]. The peculiar effects 
of narciclasine seem to arise from the functional groups and conformational 
freedom of its C-ring, with the 7-hydroxyl group believed to be important in its 
biological activity [21]. Narciclasine, is one of the most important antineoplastic 
Amaryllidaceae alkaloids. It inhibits HeLa cell growth, and is active against a 
variety of tumor cells. No effect has been observed toward solid tumors. Some 
alkaloids of this type, such as trisphaeridine, possess high antiretroviral activities 
[22]. 
 Montanine types, are a group with little information. Evidente el al. (2004), 
reported some data about pancracine, which shows antibacterial activity against 
S. aureus and Pseudomonas aeruginosa. 
 Galanthamine types, have like founder galanthamine. This alkaloid, originally 
isolated from Galanthus nivalis L. in the 1940, is a long-acting, selective, 
reversible and competitive inhibitor of acetylcholinesterase, in fact this product 
is marketed as a hydrobromide salt under the name Razadyne, formely 
Reminyl, for the treatment of Alzheimer’s disease. Galanthamine has other 
noteworthy pharmacological actions, including an ability to amplify the nerve-
muscle transfer. It is also known to cause bradycardia or atrioventricular 
conduction disturbance, has long been used as a reversal agent in anesthetic 
practice, inhibits traumatic shock, and has been patented for use in the treatment 
of nicotine dependence [23]. 
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1.3 CRINUM ANGUSTUM STEUD. 
The genus Crinum, belonging to Amaryllidaceae family, includes approximately 160 
species present in warm temperate regions of the world [24]. Cross-hybridization of 
Crinum plants is rather widespread, mainly due to their particular interest as ornamental 
plants. Indeed, several species of this genus are cultivated for both ornamental and 
therapeutic purposes [15]. The ethnobotanical use of Crinum plants have been 
developed in different parts of the world. For instance, the bulbs of C. asiaticum L. were 
used in India as tonic, laxatives and expectorants. The C. latifolium L. from India was 
applied to treat rheumatism, abscesses, earaches and as a tonic. The roots of some 
Crinum species were used in Africa to treat urinary infections, coughs and colds, renal 
and hepatic conditions, sores, sexually transmitted disease and backache [25].  
In this work was examined Crinum angustum Steud., a hybrid between C. asiaticum 
var. asiaticum and C. zeylanicum [26]. Plant at the pre-flowering stage were collected in 
the greenhouse of the Botanical Garden of Bologna University, and was identified by 
Prof. Lucia Conte. A voucher specimen (No. BOLO0507744) was deposited in the 
Herbarium of the University Museum System (SMA), Bologna University, Italy. In 
figure 1.2 is reported a picture of Crinum angustum Steud. 
 
 
Fig. 1.2 Flower and leaves of Crinum angustum Steud. 
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1.4 PANCRATIUM ILLYRICUM L. 
Amongst the Amaryllidaceae, the genus Pancratium comprises over 20 species widely 
spread throughout the Old World (Asia, Africa and Europe). Some of them have been 
studied for their potential therapeutical use [27]. Amongst these, Pancratium maritimum 
is one of the most exhaustively investigated species, and over half of all the alkaloids 
isolated from Pancratium plants have been identified in this species. Conversely, very 
few reports are available on Pancratium illyricum L., a species endemic to Sardinia, 
Corsica and the Tuscan archipelago [28]. In a recent work aimed at identifying new 
cytotoxic compounds from different Sardinian plants, a considerable activity against 
both human and bacterial topoisomerase has been demonstrated for three compounds 
isolated from bulbs of this species [29]. 
In the present work both bulbs and leaves of Pancratium illyricum L. was analysed. 
Plant was collected during the flowering period in the South of Sardinia (Punta San 
Michele, CA, Italy), and identified by Professor Mauro Ballero (University of Cagliari, 
Italy). A voucher specimen (CAG 1365) has been deposited in the Institute of Botany, 
University of Cagliari. In figure 1.3 is shown a picture of Pancratium illyricum L. 
 
 
Fig. 1.3 Plant and flowers of Pancratium illyricum L. from Sardinia 
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1.5 LEUCOJUM NICAEENSE ARD. 
Leucojum L. is an interesting genus from a taxonomic and cytological point of view. It 
consists of 12 taxa, many of which are cultivated for their ornamental value. Its 
distribution, almost all over Europe, includes a wide variety of habitats. The main 
concentration of species however, is found in the Mediterranean region, which can be 
considered as the center of diversity for the genus [30]. The genus Leucojum with L. 
aestivum L., was one of the first sources of galanthamine, and the first plant of the 
Amaryllidaceae family that has been studied for in vitro development [31]. 
Leucojum nicaeense Ard., plant belonging to this genus, endemic from the Maritime 
Alps of southern France and NW-Italy, is included in the World Red List as an 
endangered species and it is classified as vulnerable. For the EU it is part of the Annex 
II of Habitat Directive (issued by WCMC) for threatened plants [32]. For this reason, 
even if potential source of alkaloids to pharmacological interest, is not yet investigated 
in phytochemical field. 
In this work have been examined, in collaboration with the Research Council for 
Agricultural Experimentation (CRA-FSO) of Sanremo, micropropagated plants (both in 
vitro and in greenhouse acclimatized) of L. nicaeense Ard. 
A voucher specimen (B100341634) of original plant has been deposited in the Botanical 
Museum of Berlin (Germany). In figure 1.4 is shown a flower of Leucojum nicaeense 
Ard. 
 
 
Fig. 1.4 Flower of Leucojum nicaeense Ard. 
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CHAPTER 2 
OXIDATIVE STRESS AND ANTIOXIDANTS AGENTS 
2.1 INTRODUCTION 
Oxidative stress is a pathological condition caused by the breakdown of the 
physiological balance in organism, between production and elimination of oxidants 
chemical species by the antioxidant defence systems. All organisms keep a reducing 
environment within their cells. The cellular redox environment is preserved by enzymes 
which maintain the reduced state through a constant input of metabolic energy. Eventual 
disturbance in this normal redox state could cause toxic effects, producing peroxides 
and free radicals that damage all components of the cell, including proteins, lipids and 
DNA. The oxidant species and free radicals play important physiological roles, such as 
the defence against bacteria, the transmission of biochemical signals between cells, the 
blood pressure control. Is only their excess, generally refers to one or more classes of 
oxidants, to be implicated in oxidative stress. 
Free radicals of importance in living organisms include hydroxyl (OH

), superoxide 
(O2

), nitric oxide (NO

), and peroxyl (RO2

). Peroxynitrite (ONOO

), hypochlorous 
acid (HOCl), hydrogen peroxide (H2O2), singlet oxygen, and ozone (O3) are not free 
radicals but can easily lead to free-radical reactions in living organisms. The term 
“reactive oxygen species” (ROS) is often used to include not only the radicals OH, 
RO2

, NO and O2

 but also the non radicals HOCl, 
1
O2, ONOO
−
, O3, and H2O2 [33]. 
 
2.2 RADICAL FORMATION 
The radicals are formed as result of acceptance or loss of an electron, and as result of 
the homolytic cleavage of a covalent bond: the two electrons are separated 
symmetrically forming two reactive intermediates each of which has an unpaired 
electron. The presence of electron in an aerobic environment leads to the formation, 
initially of the superoxide radical, then of hydrogen peroxide and finally the hydroxyl 
radical. The first step in the ROS generation, is represented by the oxygen acquisition of 
sufficient energy to reach the singlet state and the subsequent acquisition of an electron, 
thus giving rise superoxide anion (O2

). 
The enzyme superoxide dismutase (SOD), adding two protons and an electron converts 
the superoxide anion to peroxide hydrogen (H2O2). O2
 
and H2O2 react with each other  
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resulting in the formation of an oxygen molecule, a hydroxyl anion, and a radical 
hydroxyl (OH
 •
) that between oxygen radicals, is the most toxic molecule and 
more dangerous [34]. In addition to oxygen radicals are reactive species centered on the 
nitrogen such as nitric oxide (NO 
•
), nitric dioxide (NO 2 •), which as ROS, play roles in 
physiological conditions of extreme importance, but that if produced in excess, can 
cause cellular stress. 
Free radicals and other reactive species not radical type, are produced in biological 
systems, both through processes endogenous, that following exposure to exogenous 
sources. For example among the physiological processes include:  
- Aerobic respiration in mitochondria 
- ROS formation in the cell membrane 
- Peroxisome activity 
- ROS production in endoplasmic reticulum 
ROS production can occur also by external agents, as chemical, physical, and natural. 
 
2.3 ANTIOXIDANT SYSTEMS 
Organisms have a complex system of defence against oxidative stress, constituted by 
antioxidant agents both endogenous and exogenous, enzymatic or not, with different 
mechanism of action and chemical characteristics. Antioxidants exert their action by 
counteracting or by preventing the oxidation of other molecules, preventing the radical 
formation, or giving to these an electron. The Human organism possess defense systems 
extremely effective, as the catalytic activity able to sequester ROS directly or indirectly, 
substances that act as chemical traps against free radicals, and which restore antioxidant 
defences. Among these are antioxidants enzymes that catalyze the transformation or 
destruction of ROS, chelating compounds, and molecules that can act as a scavenger, 
like many vitamins, GSH (reduced glutathione), co-enzymes and polyphenols. 
The main antioxidant enzymes, present in the cytosolic, are: 
- Catalase (CAT), located mainly in peroxisomes, and cytosolic fraction, is an enzyme 
able to protect cells from the toxic effects of hydrogen peroxide (H2O2) by 
catalysing its decomposition into molecular oxygen and water, without the 
production of free radicals. 
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- Glutathione peroxidase (GSH-Px), a metal- enzyme containing selenium, which 
performs the antioxidant function at the intracellular level. Oxidative stress produces 
peroxides that can be reduced by using the GSH through glutathione peroxidase into 
water and alcohol. 
- Superoxide dismutase (SOD) is a metal-enzyme that catalyzes the dismutation of the 
superoxide ion to molecular oxygen and peroxide hydrogen. 
- The NADP(H): quinone oxidoreductase 1 (NQO1), sometimes considered an enzyme 
of phase II, is an enzyme belonging to the class of oxidoreductases, that catalyzes 
the formation of semiquinone. 
Quinones are a group of very common substrates, which may have deleterious effects, 
such as the ability to attack nucleophiles and generate reactive oxygen species, which 
are reduced with a mechanism of transfer of ions hydride to generate the corresponding 
derivative hydroquinonic. The NQO1 has also an important role in the metabolism of 
endogenous quinones such as vitamin E and ubiquinone. For example the reduction of 
ubiquinone to work of NQO1 regenerates ubiquinol, which possesses strong antioxidant 
properties [35]. 
 
2.4 OXIDATIVE STRESS AND RELATED DISEASES 
Oxidative stress refers to all changes which produced in tissues, cells and biological 
macromolecules, when following an alteration of the balance between intracellular 
antioxidant defenses and pro-oxidant elements, with accumulation of radical species. 
The wide variety of mechanisms that can be activated as a consequence of redox 
imbalance can significantly contribute to the development of numerous pathological 
conditions, in particular, cancers, inflammatory pathologies, diabetes, ischemia, 
cardiovascular disease and neurodegenerative diseases. However, it is still unclear 
whether oxidative stress is among the main causes, or between the events that occur 
during the pathological process and that contribute to the progression of the disease. For 
example, in Parkinson's disease, is unlikely that oxidative stress is the primary event, of 
the degenerative process that leads to the depletion of dopaminergic neurons, but it is 
certain, however, that during the disease to occur oxidative phenomena involved 
substantially into progression of neuronal damage. ROS appear to be involved in many 
inflammatory processes, which, although not produce, certainly characterize various 
diseases associated with aging. 
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CHAPTER 3 
ALZHEIMER DISEASE 
3.1 INTRODUCTION 
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder associated with a 
rapid cognitive decline with an average of survival of 5-10 years after diagnosis. 
Furthermore, AD clearly differs from the normal aging in that it causes dramatic loss of 
synapsis, neurons and brain activity in specific anatomical regions, and results in 
massive atrophy and gliosis. 
The factors that cause some individuals to depart from the relatively benign of normal 
aging brain and instead undergo the pathological cascade that leads to AD are unknown 
[36]. 
Although memory loss is usually the initial and most prominent problem, deficits in 
cognitive domains other than memory can occur in the early stages of disease in some 
patients. Final deterioration leads to a bedridden, mute, incontinent, and unresponsive 
state, which mimics the persistent vegetative state. 
Pathologically AD is characterized by the presence of two insoluble protein aggregates, 
senile plaques formed from the peptide β-amyloid (Aβ) and neurofibrillary tangles 
composed of hyperphosphorylated tau protein [37]. In rare familial AD, the cause of 
disease is autosomal dominant mutations in Aβ precursor protein (APP) or the Aβ-
producing enzymes presenilins (PSEN1 or PSEN2), which are all thought to lead to 
increased levels of aggregated Aβ [38]. Likewise, mutations in tau (MAPT) that 
predispose it to aggregation can cause specific diseases that involve profound 
neurodegeneration and dementia. Thus, like in other neurodegenerative diseases such as 
Huntington's disease (HD) and Parkinson's disease, the formation of toxic insoluble 
aggregates seems to be a key pathogenic step. However, it is not known why these Aβ 
and tau aggregates accumulate in AD patients nor how they contribute to neuronal 
dysfunction, particularly for Aβ deposits, which can often be found in the brains of 
elderly non-demented subjects [39].  
An important goal of AD research is to identify interventions that maintain brain 
function, potentially by inhibiting the formation or improving the clearance of 
neurotoxic aggregates, or by promoting resistance to, or recovery from, damage.  
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The clinical presentation of AD is heterogeneous and insidious, and the psychological 
and financial effects of AD on caregivers and family members are significant. 
 
3.2 THERAPY IN ALZHEIMER’S DISEASE 
More than a decade after the first approval of the use of Acetylcholinesterase inhibitor 
on patients with Alzheimer’s disease, still not have a single treatment or combination 
therapy that can effectively stop or reverse the progression of such neurodegenerative 
disease.  
Probably there is not one single cause, but several factors are important to describe the 
etiology of the disease. Therefore, combination of compounds, which act at more than 
one target site, could be useful for AD treatment. 
To date, there are only 5 medications approved by Food Drug Administration (FDA) to 
treat AD. 
They include 4 Acethylcholinesterase inhibitor (AChEIs), and one N-methyl-D-
aspartate (NMDA) antagonist, molecule that regulates the activity of glutamic acid 
receptor. 
 
3.3 CHOLINESTERASE INHIBITORS 
The cholinergic hypothesis Of AD concludes that cholinergic system in the basal 
forebrain are affected early in the disease process including loss of the acetylcholine 
neurons, loss of enzymatic function for acetylcholine synthesis and degradation, 
resulting in memory loss as well as deterioration of other cognitive and noncognitive 
functions such as neuropsychiatric symptoms. A strategy to enhance the cholinergic 
transmission by using AChEIs to delay the degradation of acetylcholine between the 
synaptic cleft was then proposed. In 1993 the first FDA approved AChEIs, tacrine 
boomed out but it was no longer use because of its high prevalence of hepatotoxicity. 
FDA approved another three AChEIs: donepezil (1996), rivastigmine (2000), and 
galanthamine (2001) in the following years. 
These drugs have been regarded as the standard and first-line treatment for of AD. 
Systemic reviews, showed benefit on cognitive functions, activities of daily living 
(ADL), and global functions for patients mild to moderate AD. 
 20 
 
Certainly these drugs do not lead to the cure of AD, but to continue to identify AChEIs 
with fewer adverse effects and capable of alleviate symptoms of AD also in advanced 
stage, could represent a valid area to study, and Amaryllidaceae plants are good sources 
of molecules with this activity. 
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CHAPTER 4 
MATRIX METALLOPROTEINASES AND REGULATION OF CELL 
BEHAVIOR 
4.1 INTRODUCTION 
Extracellular proteinases are required for numerous developmental and disease-related 
processes. The ability to degrade extracellular proteins is essential for any individual 
cell to interact properly with its immediate surroundings and for multicellular organisms 
to develop and function normally. On this basis, a family of related enzymes has been 
identified in species from hydra to humans and collectively called matrix 
metalloproteinases (MMPs), because of their dependence on metal ions for catalytic 
activity, their potent ability to degrade structural proteins of the extracellular matrix 
(ECM), and specific evolutionary sequence considerations that distinguish them from 
other closely related metalloproteinases. 
Essentially Matrix metalloproteinases (MMPs) constitute a multigene family of over 25 
secreted and cell surface enzymes that process or degrade numerous pericellular 
substrates. Their targets include other proteinases, proteinase inhibitors, clotting factors, 
chemotactic molecules, latent growth factors, growth factor–binding proteins, cell 
surface receptors, cell-cell adhesion molecules, and virtually all structural extracellular 
matrix proteins. Thus MMPs are able to regulate many biologic processes and are 
closely regulated themselves [40]. 
In addition to their ECM substrates, MMPs also cleave cell surface molecules and other 
pericellular non-matrix proteins, thereby regulating cell behavior in several ways [41]. 
Thus like the many proteins they modify, the MMPs influence diverse physiologic and 
pathologic processes, including aspects of embryonic development, tissue 
morphogenesis, wound repair, inflammatory diseases, and cancer [42]. 
At present, 25 vertebrate MMPs and 22 human homologues have been identified and 
have been classified according to substrate specificity and are often referred to as: 
collagenases, gelatinases, stromelysins, martilysins, and membrane-type MMPs. All 
contain Zn 
2+
 at the catalytic site as well as an additional zinc ion and calcium ions for 
stability. Individual MMPs are referred to by their common names or according to a  
 22 
 
sequential numeric nomenclature reserved for the vertebrate MMPs. In addition, they 
are often grouped according to their modular domain structure. In this regard, all MMPs 
have an N-terminal signal sequence (or “pre” domain) that is removed after it directs   
 
synthesis to the endoplasmic reticulum. Thus most MMPs are secreted; however, six 
display transmembrane domains and are expressed as cell surface enzymes. The pre 
domain is followed by a propeptide “pro” domain that maintains enzyme latency until it 
is removed or disrupted, and a catalytic domain that contains the conserved zinc-binding 
region. The catalytic domain dictates cleavage-site specificity through its active site 
cleft, through specificity sub-site pockets that bind amino acid residues immediately 
adjacent to the scissile peptide bond, and through secondary substrate-binding exosites 
located outside the active site itself [43]. In figure 4.1 are shown domain structure in 
different kinds of MMPs. 
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Fig. 4.1 Domain structure in different kinds of MMPs 
 
Most of the MMPs are synthesized as inactive latent enzymes. Conversion to the active 
enzyme is generally mediated by activator systems that include plasminogen activator 
or the pro-hormone convertase, furin. MMP activity is regulated by a group of 
endogenous proteins, called, tissue inhibitor of metalloproteinases (TIMPs) that bind to 
active and alternative sites of the activated MMP. 
The TIMPs represent a family of at least four 20–29-kDa secreted proteins (TIMPs 1–4) 
that reversibly inhibit the MMPs in a 1:1 stoichiometric fashion. Individual TIMPs 
differ in their ability to inhibit various MMPs. In addition, the TIMPs differ in terms of 
their gene regulation and tissue-specific patterns of gene expression [44]. 
To date, no TIMP receptors have yet been identified, suggesting that TIMPs may act as 
decoys for various signaling molecules. TIMPs are not the only endogenous MMP 
inhibitors. Indeed, α2-macroglobulin is a major endogenous inhibitor of the MMPs, and  
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its importance may have been overlooked due to the recent emphasis placed on the 
TIMPs. Because α2-macroglobulin is an abundant plasma protein, it represents the 
major inhibitor of MMPs in tissue fluids, whereas TIMPs may act locally. Moreover, 
α2-macroglobulin plays an important role in the irreversible clearance of MMPs, 
whereas TIMPs inhibit MMPs in a reversible manner. 
 
4.2 MMPs AND DISEASE 
Studies using relevant disease models in MMP-deficient animals have demonstrated the 
contribution of MMPs to disease processes. In the cardiovascular area, MMPs have 
been strongly associated with aneurysms [45], with atherosclerotic plaque rupture [46], 
with myocardial infarction, left ventricular remodeling and ultimate cardiac rupture 
[47], as well as cerebral ischemia events [48]. MMP expression is raised in multiple 
tumor types and mostly, these increases correlate with decreased survival. In both 
rheumatoid- and osteo-arthritis, MMPs are considered to be significantly responsible for 
the matrix degradation that characterizes these diseases [49]. Respiratory disorders 
including idiopathic pulmonary fibrosis, asthma, emphysema, and acute respiratory 
distress syndrome [50],are also strongly associated with MMP activity. 
Is important to emphasize that in some pathologies the correct MMP activity leads to a 
positive resolution of the disease, while in others, this result is achieved by inhibiting 
the activity of MMPs. Rather than categorizing specific MMPs as “good” or “bad”, it is 
more helpful to consider activities in particular contexts. For instance expression studies 
in humans have shown protective roles of certain MMPs. In particular, high levels of 
MMP12 correlate with better prognosis in several tumor types including hepatocellular 
and colorectal carcinoma. This is in direct contrast to the destructive role of MMP12 in 
emphysema where the elastase-degrading activity of MMP12 clearly contributes to 
pathophysiology. By generalizing it can be stated that in chronic diseases, 
inflammatory, and in some tumors, leads to disease an hyperactivity of MMPs. 
Is precisely on this type of disorders that will be tested extracts obtained in this work, 
using the collagenase enzyme from Clostridium histolyticum, as starting model for 
MMPs inhibition screening; in fact, scientific literature sees in the natural extracts, a 
great source of compounds with inhibitory activity on matrix metalloproteinase [51] 
[52]. 
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CHAPTER 5 
TYROSINASE ENZYME 
5.1 INTRODUCTION 
Tyrosinases also known as polyphenol oxidase (PPO), is a copper-containing enzyme 
widely distributed in microorganism, animals, and plants, which catalyze the oxidations 
of both monophenols (cresolase or monophenolase activity) and o-diphenols 
(catecholase or diphenolase activity) into reactive o-quinones. The term tyrosinase 
refers to its typical substrate, tyrosine. Both tyrosinase activities appear to have broad 
substrate specificities, although the enzyme has a higher affinity for the L-isomers of the 
substrates than for the corresponding D-isomers. The first biochemical investigations 
were carried out in 1895 on the mushroom Russula nigricans, whose cut flesh turns red 
and then black on exposure to air. Since this study, the enzyme has been found widely 
distributed throughout the phylogenetic scale from bacteria to mammals. The best-
characterized tyrosinases are derived from Streptomyces glausescens, the fungi 
Neurospora crassa and Agaricus bisporus. In fungi and vertebrates, tyrosinase catalyzes 
the initial step in the formation of the pigment melanin from tyrosine.  
The notable feature observed in tyrosinases from different sources is that the central 
copper-binding domain is conserved, which contains strictly conserved amino acid 
residues, including three histidines. One tyrosinase molecule can contain two copper 
atoms, and each atom of the binuclear copper cluster is ligated to three histidines. In the 
formation of melanin pigments, three types of tyrosinase (oxy-, met-, and 
deoxytyrosinase) with different binuclear copper structures of the active site are 
involved [53]. 
Melanogenesis is initiated with the first step of tyrosine oxidation to dopaquinone 
catalyzed by tyrosinase. This first step is the rate-limiting step in melanin synthesis 
because the remainder of the reaction sequence can proceed spontaneously at a 
physiological pH value. The subsequent dopaquinone is converted to dopa and 
dopachrome through auto-oxidation. 
Dopa is also the substrate of tyrosinase and oxidized to dopaquinone again by the 
enzyme. Finally, eumelanin are formed through a series of oxidation reactions from  
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dihydroxyindole (DHI) and dihydroxyindole-2-carboxylic acid (DHICA), which are the 
reaction products from dopachrome. In the presence of cysteine or glutathione, 
dopaquinone is converted to cysteinyldopa or glutathionyldopa. Subsequently, 
pheomelanin is formed. In addition to eumelanin and pheomelanin, other “melanin” 
relying on phenolic monomers different from tyrosine is termed allomelanin. The 
browning phenomenon in fruit and fungi is also usually related to oxidative 
polymerization, conceptually similar to melanogenesis. 
The main difference resides in the fact that allomelanin substantially does not contain 
dopaquinone-derived motifs as the main monomers in its structure and, on the contrary, 
is based on other quinoid building blocks [54]. 
Melanin plays an important role in protecting human skin from the harmful effects of 
sun UV radiation. Melanin also determines our phenotypic appearance. 
In Figure 5.1 is shown biosynthetic pathway of melanin. 
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Fig. 5.1 Biosynthetic pathway of melanin. TYR, tyrosinase; TRP; tyrosinase related 
protein; dopa, 3,4-dihydroxyphenylalanine; DHICA, 5,6-dihydroxyindole-2-carboxylic acid; DHI, 5,6-
dihydroxyindole; ICAQ, indole-2-carboxylic acid-5,6-quinone; IQ, indole5,6-quinone; HBTA, 5-hydroxy-
1,4-benzothiazinylalanine. 
 
 
 
 
5.2 ROLE OF TYROSINASE IN MAN AND NATURE 
Melanogenesis has been defined as the entire process leading to the formation of dark 
macromolecular pigments, i.e., melanin. Melanin is formed by a combination of 
enzymatically catalyzed and chemical reactions. It is a heterogeneous polyphenol-like 
biopolymer with a complex structure and color varying from yellow to black. The color 
of mammalian skin and hair is determined by a number of factors, the most important of 
which is in fact, the degree and distribution of melanin pigmentation. Melanin is 
secreted by melanocyte cells distributed in the basal layer of the dermis. The role of 
melanin is to protect the skin from ultraviolet (UV) damage by absorbing UV sunlight 
and removing reactive oxygen species (ROS). Various dermatological disorders result 
in the accumulation of an excessive level of epidermal pigmentation. These 
hyperpigmented lentigenes include melasma, age spots and sites of actinic damage [55]. 
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Great interest has been shown in the involvement of melanins in malignant melanoma, 
the most life-threatening skin tumors. Is evident, like tyrosinase play a key role both 
correct pigmentation of skin and in development of melanoma. This enzyme in fact, 
shows antiproliferative and apoptotic activity against malignant melanocytes. 
In the food industry, tyrosinase is a very important enzyme in controlling the quality 
and economics of fruits and vegetable. Tyrosinase catalyzes the oxidation of phenolic 
compounds to the corrisponding quinones and is responsible for the enzymatic 
browning of fruits and vegetable. In addition to the undesiderable color and flavor, the 
quinone compounds produced in the browning reaction may irreversibly react with the 
amino and sulfhydryl groups of proteins. The quinone-protein reaction decreases the 
digestibility of the protein and the bioavailability of essential amino acids, including 
lysine and cysteine [56]. 
At last, tyrosinase, plays an important role in the developmental and defensive functions 
of insects; is interested in fact in the insect molting, through the formation of the cuticle 
leads larva to insect [57]. 
 
 
5.3 TYROSINASE INHIBITORS AND THEIR IMPORTANCE 
A number of tyrosinase inhibitors from both natural and synthetic sources have been 
identified. However, the definition of “tyrosinase inhibitor” is sometimes misleading: 
many authors use that terminology in reference to melanogenesis inhibitors, whose 
action mainly resides in some interference in melanin formation, regardless of any 
direct inhibitor/enzyme interaction. Many putative inhibitors are examined in the 
presence of tyrosine or dopa as the enzyme substrate, and activity is assessed in terms of 
dopachrome formation. Thus, experimental observation of the inhibition of tyrosinase 
activity can be accomplished by one of following: 
1. Reducing agents, which causing chemical reduction of dopaquinone such as 
ascorbic acid, avoid dopachrome and melanin formations. For this reason are 
used as a melanogenesis inhibitor for their capacity to reduce back o-
dopaquinone to dopa. 
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2. o-Dopaquinone scavenger such as most thio-containing compounds, which are 
well-known melanogenesis inhibitors and react with dopaquinone to form 
colorless products. The melanogenetic process is therefore slowed until all the 
scavenger is consumed, and then it goes at its original rate. 
3. Alternative enzyme substrates such as some phenolic compounds, whose 
quinoid reaction products absorb in a spectral range different from that of 
dopachrome. When these phenolics show a good affinity for the enzyme, 
dopachrome formation is prevented, and they could be mistakenly classified as 
inhibitors. 
4. Nonspecific enzyme inactivators such as acids or bases, which non-specifically 
denature the enzyme, thus inhibiting its activity. 
5. Specific tyrosinase inactivators such as mechanism-based inhibitors, which are 
also called suicide substrates. These inhibitors can be catalyzed by tyrosinase 
and form covalent bond with the enzyme, thus irreversibly inactivating the 
enzyme during catalytic reaction. They inhibit tyrosinase activity by inducing 
the enzyme catalyzing “suicide reaction.” 
6. Specific tyrosinase inhibitors. The compounds bind reversibly to tyrosinase and 
reduce its catalytic capacity. 
Among the six types of compounds described above, only specific tyrosinase 
inactivators (5) and inhibitors (6) are regarded as “true inhibitors,” which actually bind 
to the enzyme and inhibit its activity [54]. 
The discovery and characterization of new tyrosinase inhibitors are useful for their 
potential applications, and also because there are few “true inhibitiors” available. The 
fields of interest for tyrosinase inhibitors is clear that are various: improving food 
quality and nutritional value, controlling insect pests, preventing pigmentation disorders 
and other melanin-related health problems in human beings. 
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CHAPTER 6 : 
THE PROBLEM OF MULTIDRUG RESISTANCE (MDR) AND NOSOCOMIAL 
INFECTIONS 
6.1 INTRODUCTION 
According to the World Health Organization, infectious diseases are a significant cause 
of morbidity and mortality worldwide, accounting for approximately 50% of all deaths 
in tropical countries. Infectious and parasitic diseases remain primary causes of 
pediatric mortality in developing countries, partly as a result of the HIV/AIDS epidemic 
[58]. Despite the progress made in the understanding of microbiology and the control of 
microorganisms, sporadic incidents of epidemics due to drug resistant microorganisms 
and hitherto unknown disease causing microbes pose an enormous threat to public 
health. Such negative health trends call for a new global initiative for the development 
of new strategies for the prevention and treatment of infectious disease [59]. 
Proposed solutions outlined by the Center for Disease Control as a multipronged 
approach include: prevention, improved monitoring, and the development of new 
treatments that exceed the resistance bacterial. 
It was just a few years after the introduction of penicillin that scientists began to notice 
the emergence of a penicillin resistant strain of Staphylococcus aureus, a common 
bacterium that makes up part of normal human bacterial flora. 
Since then, resistant strains of gonorrhoea, dysentery causing Shigella (a major cause of 
premature death in developing countries) and Salmonella followed in the wake of S. 
aureus. From the initial case of resistant Staphylococcus aureus, the problem of 
antimicrobial resistance has grown into a serious threat to public with economic, social, 
and medical implications that are global in scope and cross all environmental and ethnic 
boundaries [60]. 
National Nosocomial Infection Surveillance (NNIS) System data demonstrate a steady 
increase in the incidence of nosocomial infections caused by methicillin-resistant S. 
aureus (MRSA) among ICU (intesive Care Units) patients over time. MRSA now 
accounts for more than 60% of S. aureus isolates in USA hospital ICUs. In addition, the 
medical issues of these infected patients have become more complex as a result of 
sophisticated medical system, and the parallel development of infections at already 
present bacterial resistance can lead to death of the patients [61]. 
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In addition to the problem of multi-drug resistance (MRD), should consider the 
increasing development of nosocomial infections. One of the primarily responsible of 
hospital infections, is the Candida with its spp.  
Candida spp. are an important cause of nosocomial bloodstream infections (BSIs). The 
incidence of BSIs caused by Candida spp. has risen in the past 20 years [62], and 
Candida spp. are currently the fourth leading cause of nosocomial BSI in the USA. 
Mortality rates range between 29% and 76%, with an attributable mortality high as 49% 
[63]. Several Candida spp. exhibit reduced susceptibility to ﬂuconazole and others 
antifungal drugs, so, also in this case is important the development of new treatments. 
 
 
6.2 MEDICINAL PLANTS AND TREATMENT OF MICROBIAL INFECTIONS 
Naturally derived compounds have made considerable contributions to human health 
and well-being, and have been a source of inspiration for novel drug development. 
There are thousands of published scientific papers from around the globe describing the 
antimicrobial activities of plants extract. The majority of the plants had activity against 
a range of bacteria, fungi and Mycobacterium. Many of the plant species with 
antimicrobial activity were native to tropical countries, due to the extraordinary 
biodiversity of these places. 
Is important to note that, while many of the medicinal plant extracts purported to have 
antibacterial activity have only been subjected to in vitro screening, and the vast 
majority of these extracts have never been tested rigorously in animal models or 
controlled clinical trials [64]. 
In this study, the extracts and pure compounds tested, were analyzed both as regards the 
ATCC strains and on clinical isolated, with the aim to be able to approach the data 
obtained as much to a real result. 
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CHAPTER 7 : 
PLANT CELL CULTURE SYSTEMS: A POTENTIAL RENEWABLE SOURCE 
OF VALUABLE MEDICINAL COMPOUNDS 
Many higher plants are major sources of natural products used as pharmaceuticals, 
agrochemicals, and food additives. The search for new plant derived chemicals should 
thus be a priority in current and future efforts toward sustainable conservation and 
rational utilization of biodiversity. In the search for alternatives to production of 
desirable medicinal compounds from plants, biotechnological approaches, specifically, 
plant tissue cultures, are found to have potential as a supplement to traditional 
agriculture in the industrial production of bioactive plant metabolites. Cell suspension 
culture systems could be used for large scale culturing of plant cells from which 
secondary metabolites could be extracted. The advantage of this method is that it can 
ultimately provide a continuous, reliable source of natural products [65]. 
Discoveries of cell cultures capable of producing specific medicinal compounds at a rate 
similar or superior to that of intact plants have accelerated in the last few years. New 
physiologically active substances of medicinal interest have been found by bioassay. It 
has been demonstrated that the biosynthetic activity of cultured cells can be enhanced 
by regulating environmental factors, well as by artificial selection or the induction of 
variant clones. Some of the medicinal compounds localized in morphologically 
specialized tissues or organs of native plants have been produced in culture systems not 
only by inducing specific organized cultures, but also by undifferentiated cell cultures. 
The major advantages of a cell culture system over the conventional cultivation of 
whole plants are: 1) Useful compounds can be produced under controlled conditions 
independent of climatic changes or soil conditions; 2) Cultured cells would be free of 
microbes and insects; 3) The cells of any plants, tropical or alpine, could easily be 
multiplied to yield their specific metabolites; 4) Automated control of cell growth and 
rational regulation of metabolite processes would reduce of labor costs and improve 
productivity; 5) Organic substances are extractable from callus cultures.  
Advances in tissue culture, combined with improvement in genetic engineering, 
specifically transformation technology, has opened new avenues for high volume 
production of pharmaceuticals, nutraceuticals, and other beneficial substances [66]. 
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CHAPTER 8 :  
AIM OF THE STUDY 
Historically, man has used plants to supply almost all of his basic needs, and plants have 
always played a central role in traditional systems of medicine for the prevention and 
treatment of disease around the world. 
In the development of new drugs, the role of natural products has been two fold: 1) they 
may become the base for the development of a medicine, or, 2) a phytomedicine to be 
used for the treatment of disease. 
On these basis, in this study, are analysed plants extract of Amaryllidaceae family, 
plants that are known to contain secondary metabolites of high pharmacological profile, 
since they have been proven to possess antibacterial, antifungal, antiprotozoal, 
antitumoral, and acetylcholinesterase inhibitory activities [67]. 
Since these plants have never been studied, the purpose is:  
- to characterize with phytochemical studies the alkaloid extracts.  
- In the event that encounter compounds not yet classified, carry out a complete 
characterization, by establishing the properties of the compounds. 
- To test extracts on pharmacological targets, that representing both degenerative and 
chronic diseases. 
- Achieve a development of in vitro plant cell cultures, with the goal of obtaining in 
vitro production of alkaloids, equivalent to that of plant. 
The in vitro development will be made, not only for protection of the species 
biodiversity because the plants analyzed in this study are endangered, but also because 
in the case that plant will grow in vitro and will produce in the same manner of the 
original one, will be controlled the production of secondary metabolites with addition of 
elicitors. 
The pharmacological targets chosen for screening of the extracts activity, are associated 
with a wide range of disorders or diseases, not only, their activity can also be extended 
to fields such as cosmetics, food and agrochemical; just think in fact of the applicability 
that could have the inhibition of enzymes such as: Collagenase, Tyrosinase and 
Acetylcholinesterase. 
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Not least, the extracts will be tested on Multi-Drug Resistant (MDR) microorganism, 
considering the original protective role against attacks from external agents that have 
the alkaloids in plants. 
 
With the development of MDR and the consequent hospital infections, which daily 
involve discomfort and increased risk on the patient's health with a consequent increase 
in health spending, the development of new molecules with antimicrobial activity and 
not subject to bacterial resistance could open new ways for the development of new 
drugs. 
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CHAPTER 9 : 
MATERIALS AND METHODS 
9.1 EXTRACTION AND ISOLATION OF ALKALOIDS 
The extracts of three Amaryllidaceae plants of C. angustum, P.illyricum and L. 
nicaeense (all 6 micropropagated plants) were separately obtained from fresh plants, as 
follows: were crushed separately and exhaustively extracted with MeOH at room 
temperature for 72 h. The extracts were evaporated under reduced pressure. These crude 
extracts were acidified by dissolving in 100 mL H2SO4 1% (v/v) and neutral material 
was removed with n-hexane (6 x 100 mL) and CHCl3 (4 x 100 mL). The acidified 
solutions were then basified with 25% NH4OH up to pH 9-10 and extracted with CHCl3 
(4 x 100 mL) to give the chloroformic extract containing alkaloids. The extracts were 
dried with anhydrous Na2SO4, filtered and completely dried under reduced pressure. As 
regard leaf chloroformic extract of P. illyricum was subjected to vacuum liquid 
chromatography (VLC) [68] using a silica gel 60 A (6-35 μ) column with a diameter of 
1 cm and height of 4 cm. Alkaloids were eluted using n-hexane gradually enriched with 
EtOAc, then gradually enriched with CHCl3 and finally with a mixture of EtOAc and 
CHCl3 gradually enriched with MeOH. Fractions of 10 mL were collected (200 in total), 
monitored by TLC (Dragendorff’s reagent, UV 254 nm) and combined according to 
their profiles. Four main fractions were obtained and subjected to preparative TLC (20 
cm x 20 cm x 0.25 mm, silica gel 60F254). 11α-hydroxy-O-methylleucotamine (7 mg) 
was obtained in major quantities from fractions 40-53 (eluted from VLC with n-
Hexane-EtOAc, 64:36 to 56:44) through preparative TLC (EtOAc-CHCl3-CH3OH 
4:1.5:0.5 + 25% ammonia). 
 
9.2 GC-MS ANALYIS 
The extracts of C. angustum, P. illyricum and L. nicaeense (all 6 micropropagated 
plants) obtained separately were analyzed qualitatively by GC-MS analysis starting 
from a mother solution of 300 µg/mL. 
EIMS were obtained on a GC-MS Hewlett-Packard 6890 + MSD 5975 operating in EI 
mode at 70 eV. A HP-5 MS column (30 m × 0.25 mm × 0.25 μm) was used. The 
temperature program was: 100-180 ºC at 15 ºC  min
-1
, 1 min hold at 180 ºC, 180-300 ºC 
at 5 ºC min
-1
 and 1 min hold at 300 ºC. Injector temperature was 280 ºC. The flow rate  
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of the carrier gas (helium) was 0.8 mL min
-1
. In most cases the split ratio was 1:20, but 
with more diluted samples a split ratio of 1:5. 
 
9.3 HPLC-DAD ANALYSIS 
The quantitative analysis of C. angustum, P. illyricum and L. nicaeense (all 6 
micropropagated plants) obtained separately were carried out using an HPLC system 
(Jasco Corp., Tokyo, Japan) consisting of a PU-1580 pump, an LG-1580-02 ternary 
gradient unit, a DG-1580-53 three-line degasser, and a diode array (DAD) detector MD-
2018 Plus operating at 280, 240 and 220 nm, linked to an autosampler (2055 Plus). A 
Spherisorb C18 column (5 μm, ODS2, 4.6 × 250 mm, Waters Corp., Milford, MA, 
USA) was used with a flow rate of 0.7 ml/min and elution was performed under 27 °C 
temperature. The mobile phase was made up of acetonitrile:ammonium acetate 80 mM 
pH 6.0 (30:70). Data were acquired and processed by the Chromnav Chromatography 
Data system software (Jasco). 
 
9.4 GENERAL 
All chemical products used were provided by Sigma Aldrich. UV spectra were obtained 
on a DINKO UV2310 instrument and IR spectra were recorded on a Nicolet Avatar 320 
FT-IR spectrophotometer. Biological assays were performed using a microplate reader, 
Victor X3 Perkin-Elmer (Perkin-Elmer Inc., Boston, MA, USA) and dataanalyzed with 
the software Work Out 2.5 or in a Jasco V-530 spectrophotometer (Jasco Europe, 
Cremella, Italy). Statistical analyzes were obtained from software GraphPad Prism 5. 
 
9.5 NMR ANALYSIS 
Compound isolated from the leaves extract of P. illyricum was subjected to NMR 
analysis as follows: NMR spectra (one and two dimensional) were recorded in a Varian 
VXR 500 MHz, instrument using CDCl3 as the solvent and TMS as the internal 
standard. Chemical shifts were reported in δ units (ppm) and coupling constants (J) in 
Hz. 
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9.6 CYTOTOXICITY ASSAY 
The human embryo lung fibroblast (HEL) were grown in DMEM (Gibco®, Life 
technologies) supplemented with 10% foetal calf serum (Lonza, BioWhittaker), 10U 
penicillin and 50 μg/ml streptomycin at 37°C. For each set of experiments, cells were 
seeded into 96-well plates at 10
4
 cells/well and incubated with 2-fold serial dilutions 
starting from 2.50 mg/mL of the extract sample; there were positive controls containing 
cells in regular medium and solvent controls containing cells in 2-fold serial dilutions of 
DMSO (from 6.25 %). Cells were grown for 24 h at 37°C, then 50 µL of XTT labeling 
mixture (Cell Proliferation kit II, XTT, Roche) were added to cells, followed by a 6-h 
incubation allowing formazan production. Finally, OD was measured at 450/630 nm by 
using the microplate reader. The cytotoxic activity was expressed as the IC20 (20% 
inhibitory concentration) after a 24 h-incubation period, relative to the control. 
 
 
9.7 ANTIOXIDANTS ASSAYS 
9.7.1 DPPH AND ABTS ASSAY 
The DPPH assay was performed according to the method of Venditti et al. (2013) [69], 
with some modiﬁcations. Stock solutions of plants extract were prepared in 
water/DMSO (90-10) to obtain diﬀerent ﬁnal concentrations (from 5 to 200 μg/mL in 
the assay) to calculate the IC50 value. One and a half milliliters of a 0.05 mM DPPH 
methanol solution was added to diﬀerent concentrations of plants extract and allowed to 
react at room temperature. The assay was performed in a ﬁnal volume of 2 mL. After 20 
min, the absorbance (Abs) values were measured at 517 nm and converted into 
percentage antioxidant activity using the following formula: 
Scavenging capacity% = [1 (Abs sample /Abs control) 100] 
The DPPH solution plus methanol was used as a negative control, whereas Trolox (TR) 
at diﬀerent concentrations (from 5 to 40 μM) was used as reference antioxidant 
compound. The IC50 values were calculated by logarithmic regression of plots, where 
the x-axis represents the individual plants extract or reference compound concentrations 
and the y-axis the average percentage of scavenging capacity. 
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The ABTS assay was performed according to the method of Venditti et al. (2013) with 
some modiﬁcations. ABTS•+ radical was generated by mixing a 2 mM ABTS solution 
with 7 mM K2S2O8 and incubating in the dark for 24h at room temperature. Before 
usage, the ABTS •+ solution was diluted (1−25 mL methanol) to obtain an Abs value of 
0.7 at 734 nm. Upon addition of 1 mL of the diluted ABTS•+ solution to 10 μL of 
reference compound or plants extract stock solutions (from 5 to 200 μg/mL), the Abs at 
734 nm was recorded after 1 min. The ﬁnal TEAC value of plants extract was calculated 
by comparing ABTS•+ decolorization with that of Trolox. The IC50 value was 
calculated as described above. 
 
9.7.2 β-CAROTENE BLEACHING ASSAY 
Prevention of the autoxidation of emulsiﬁed linoleic acid was determined by modifying 
method of Venditti et al. (2013). Brieﬂy, 20 μL of diﬀerent plants extract or reference 
compound stock solutions (50, 100, 150, and 200 μg/mL) was added to the microplate 
wells (Costar 3599) in duplicate. Then, 10 μL of linoleic acid, 47 μL of Tween 40, and 
2.5 mL of β-carotene (2 mg/mL in chloroform) were placed in a ﬂask. After removal of 
chloroform with nitrogen gas, 22,5 mL of distilled hot water (50 °C) and 2.5 mL of 0.1 
M sodium phosphate buﬀer (pH 6.8) were added to the same ﬂask and shaken well. An 
amount of 0.2 mL of the linoleic acid−β- carotene emulsion were transferred rapidly to 
each well, kept under constant temperature (50 °C), and the Abs at 490 nm monitored 
for 60 min. H2O (20 μL) and reference compound (20 μL) at diﬀerent concentrations 
(0.25, 0.5, 1, 1.5, and 2.5 mM) were used as negative and positive controls, 
respectively. The diﬀerence in Abs at 50 and 5 min (Δ = Abs 50 min − Abs 5 min) was 
calculated. Results are expressed in terms of percentage bleaching inhibition of the 
initial linoleic acid−β-carotene emulsion by the test samples according to the following 
equation: 
%bleaching inhibition = [1-(Δabs sample /Δ Abs negative control) 100] 
IC50 values were calculated by logarithmic regression in terms of micromolar or µg/mL. 
The antioxidant activity was also expressed as TEAC, by comparing IC50 values 
obtained for plants extract with that of Trolox (TR). 
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9.8 STUDY OF THE ENZYMATIC INHIBITION ACTIVITY 
9.8.1 INHIBITION OF THE ACETYLCHOLINESTERASE (ACHE) ENZYME 
The assay for measuring AChE activity was performed as described by López et al. 
(2002). In brief, 50 μL of AChE in buffer phosphate (8 mM K2HPO4, 2.3 mM 
NaH2PO4, 0.15 mM NaCl, 0.05% Tween 20, pH 7.6) and 50 μL of the sample dissolved 
in the same buffer were added to the wells. The plates were incubated for 30 min at 
room temperature before the addition of 100 μL of the substrate solution (0.1 M 
Na2HPO4, 0.5 M 5,5’-dithiobis-2-nitrobenzoic acid (DTNB), 0.6 mM acetylthiocholine 
iodide, pH 7.5). The absorbances were read in a microplate reader Victor X3 Perkin 
Elmer (Perkin Elmer Inc., Massachusetts USA) at 405 nm after five minutes. 
Galanthamine hydrobromide was used as a positive control. The IC50 of bulbs and 
leaves extract of P. illyricum, 11α-hydroxy-O-methylleucotamine and galanthamine 
hydrobromide was determined in triplicate and the results are presented as mean ± 
standard deviation. 
 
9.8.2 INHIBITION OF THE COLLAGENASE ENZYME WITH SYNTHETIC 
SUBSTRATE 
The alkaloid extracts of C. angustum, P. illyricum (bulbs and leaves) and L. nicaeense 
were tested on Collagenase assays that uses FALGPA as substrate. 
The Clostridium hystolyticum collagenase (EC.3.4.23.3) assay was based on the assay 
described by van Wart et al. [70], slightly modified for use with a 96-well microtiter 
plate: enzyme was dissolved in 50 mM tricine buffer (with 10 mM CaCl2 and 400 mM 
NaCl), pH 7.5, to furnish 0.8 units/mL (according to the supplier’s activity data); 
substrate FALGPA was prepared 2 mM in that same buffer. An amount of 25 µL buffer, 
25 µL H2O or inhibitor, and 25 µL enzyme was loaded each well of the 96-well 
microtiter plate, and after 15 min of preincubation, 50 µL of substrate was added. 
Absorbance was measured at 340 nm immediately and at 2-min intervals for 20 min. 
Enzyme activity was estimated by linear regression of the absorbance values recorded 
during that time. For comparative purposes we also assayed EGCG (epigallocatechin 
gallate) as a known inhibitor. 
The percentage inhibition of enzyme activity was calculated by the following formula: 
%inhibition = [1- (Δ Abs/min sample / Δ Abs/min negative control) × 100] 
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IC 50 (concentration necessary for 50% inhibition of enzyme activity) was calculated by 
constructing a linear regression curve. A Lineweaver-Burk (L-B) plot was constructed to 
calculate the kinetic parameters (Km expressed in mM and Vmax in nmol/s) of the 
enzymatic reaction without and with P. illyricum bulbs extract, at the IC50  
concentration. 
Four substrate concentrations in the range of 0.5 mM-2.5 mM were assayed to elucidate 
the mechanism of inhibition by the bulbs extract of P. illyricum. 
 
 
9.8.3 INHIBITION OF THE COLLAGENASE ENZYME WITH COLLAGEN 
SUBSTRATE 
Plants extract of C. angustum, P. illyricum (bulbs and leaves), L. nicaeense, and three 
pure compound, lycorine, vittatine and hordenine, respectively at concentrations of 333 
µg/mL for extracts and 0.4 mM for pure compounds, were tested with this assay, where 
the amount of hydroxyproline (4-hyp) which is produced is directly proportional to the 
amount of the degraded collagen. Method of Mandrone et al. [71] foresees: Collagen 
from bovine tendon (2 mg) was placed in 1.5 mL test tubes with 100 µL of tested 
compounds or water (negative control) and 100 µL of tricine buffer 50 mM. After 1h of 
incubation, 50 µL of a 2mg/mL collagenase stock solution (from Clostridium 
hystolyticum) was added to the mixture to obtain a final volume of 300 µL. The samples 
were incubated at 37°C (in stove) for 24h. After the request incubation time, samples 
were vigorously vortexed and centrifuged for 10 min at 12000 rpm. This procedure 
allows to obtained the non-hydrolyzed collagen packed in the bottom of the tube, thus 
150 µL of supernatant were transferred in another test tube and totally volume 
evaporated in Speed-wac at 80°C for 1h. This step is necessary in order to dried and 
concentrate the samples moreover. The high temperature allow to a complete H-Pro 
release from small amino acids sequences derived from the hydrolysis of the starting 
collagen. Then, 50 µL of deionized water were added to each sample and vortexed. 
Finally, 100 µL of chloramine T were added and allows to react for 20 min, after that 50 
µL of Earlich reactive were added and simples were incubated for 5 min in a 56 °C bath.  
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A calibration curve was constructed using 50 µL of standard H-Pro at different 
concentration (from 0 to 50 µM) treated in same conditions of the samples. As a 
reference compound was used EGCG. 
Absorbance was recorder in microplate reader at 557 nm and the 4-hyp concentration 
was calculated by interpolation in the calibration curve.  
% Inhibition of collagen degradation was obtained by the following formula: 
                          % inhib Coll. Degr. = [1- ([4-hyp]sample/ [4-hyp]Neg ctrl)] x100 
 
 
 
9.8.4 INHIBITION OF THE TYROSINASE (PPO) ENZYME 
Plants extract of C. angustum, P. illyricum (bulbs and leaves), L. nicaeense, and three 
pure compound, lycorine, galanthamine and hordenine, were tested with Tyrosinase 
assay. The tyrosinase inhibition assay was performed by Venditti et al. (2013). In the 
Mushroom tyrosinase (EC 1.14.18.1), nine units of enzyme (1 unit being deﬁned by the 
producer as the ΔA 280 of 0.001 min−1 at pH 6.5 at 25 °C in 3 mL of reaction mix 
containing L-tyrosine) and plants extract at concentrations of 250 µg/mL were 
incubated for 5 min in 0.1 M sodium phosphate buﬀer, pH 6.8, in 0.1 mL ﬁnal volume. 
The speciﬁc activity of the enzyme is 1715 U/mg. L-DOPA (ﬁnal concentration = 3 
mM) was added to start the reaction, and the formation of dopachrome was immediately 
monitored for 5 min at 490 nm in a microplate reader under a constant temperature of 
30 °C. ΔAbs values were calculated in the ﬁrst 240 s and referred to 1 min. The 
percentage inhibition of enzyme activity was calculated by the following formula: 
%inhibition = [1- (Δ Abs/min sample / Δ Abs/min negative control) × 100] 
A negative control was obtained by adding water, instead a positive control was 
performed using kojic acid, a wellknown tyrosinase inhibitor. 
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9.9 ANTIMICROBIALS ASSAYS 
9.9.1 ANTIBACTERIAL AND ANTIFUNGAL ASSAY ON ATCC STRAINS 
The following ATCC (American Type Culture Collection) strains were used: 
Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), 
Enterococcus faecalis (ATCC 29212), Streptococcus pyogenes (ATCC 19615), 
Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Klebsiella 
pneumoniae (ATCC 9591), Proteus mirabilis (ATCC 9921), Candida albicans (ATCC 
10231), C. tropicalis (ATCC 13803), C. parapsilosis (ATCC 22019), C. glabrata 
(ATCC 15126). 
In vitro antimicrobial activity was determined by a broth micro-dilution method using 
96-well plates and according to National Committee for Clinical Laboratory Standards 
(NCCLS)-recommended procedures. Mueller-Hinton (MH) broth (Bio-Rad) was used 
for all microbial strains, except for S. pyogenes which was grown in MH broth 
supplemented with 3% lysed horse blood (Bio-Rad). 
Microbial suspensions at 5 × 105 CFU/mL were incubated with 2-fold serial dilutions 
starting from 2.5 mg/mL of extract sample (at least 6 dilutions). The subsequently 
controls were included in all experiments: extract-free growth control, bacterial 
inoculum tested with 250 µg/mL of gentamicin (Sigma-Aldrich) or fungal inoculum 
with 8 µg/mL Amphotericin (Sigma-Aldrich) (positive control), 2-fold serial dilutions 
of the tested extract inoculated with blank medium without the inoculums, measuring 
both the background turbidity and the sterility of all procedures (negative control), and 
2-fold serial dilutions of DMSO (starting from 6.25% in broth medium) inoculated with 
the microbial suspension assessing the interference effect of the solvent (solvent 
control). The microplates were incubated at 37°C for 8-24 h (and 48 h for Candida 
albicans) and microbial growth was estimated as optical density (OD at 630 nm) 
determined by the Multiskan Ascent (Thermo Scientific) microplate reader. Results 
were evaluated as follow: for each sample the net OD value was calculated (ODsample - 
ODnegative control), then the concentration required to produce 50% growth inhibition 
(IC50 value) was determined, relative to the solvent control. The extracts was assayed in 
quadruplicate and repeated in three different days, for each microorganism. 
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9.9.2 ANTIBACTERIAL AND ANTIFUNGAL ASSAY ON CLINICAL 
ISOLATES 
The same analytical procedure used for the ATCC strains was used for clinical isolates. 
The multidrug resistant (MDR) Klebsiella pneumoniae clinical isolates (resistant to β-
lactams, cephalosporins, fluoroquinolones, aminoglycosides, macrolides, tetracyclines 
and carbapenems), the MRSA, and Candida albicans clinical isolates were from 
patients hospitalized in the St. Orsola-Malpighi University Hospital in Bologna, Italy. 
Routine biochemical identification and antimicrobial susceptibility testing were carried 
out using the Vitek2 semi-automated system (BioMérieux, France). 
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9.10 DEVELOPMENTS OF IN VITRO PLANT CELL CULTURES 
9.10.1 SELECTION OF MEDIA FOR IN VITRO DEVELOPMENT 
For in vitro development of C. angustum and P.illyricum plants were tested three 
different media, indicatively called as: MS8 (callus medium), MSL (organogenetic 
medium), and MSC (shoot formation medium). 
- MS8: MS medium (Murashige and Skoog) [72], supplemented with 2,4-
dichlorophenoxyacetic acid (0.5 mg/L), kinetin (0.2 mg/L), 3% sucrose and 0.3% 
Phytagel. 
- MSL: MS medium, supplemented with 1-Naphthaleneacetic acid (1.15 mg/L), 6-
Benzylaminopurine (2 mg/L), 3% sucrose and 0.3% Phytagel. 
- MSC: MS medium, supplemented with 2,4-dichlorophenoxyacetic acid (4mg/L), 6-
Benzylaminopurine (2mg/L), 3% sucrose and 0,3% Phytagel. 
For micropropagated plants of L. nicaeense, developed by the Center for Research in 
Agriculture (CRA) in Sanremo, the medium used for propagations consisted in: MS 
medium (Murashige and Skoog) supplemented with Indol butyric acid (0.5 mg/L), 3% 
sucrose, and 0.3% phytagel; called by us for convenience IBA medium. 
 
9.10.2 EXPLANTS FROM IMMATURE FRUITS 
For in vitro cell cultures development, immature fruits of C. angustum and P. illyricum 
were selected. 
Fruits were excised, disinfected with 70% ethanol for 3 min, followed by sodium 
hypochloride solution (20% commercial bleach, v/v) for 10 min, and then rinsed with 
sterile distilled water 6–7 times. The disinfected explants were aseptically transferred to 
Petri dishes containing MS medium called MS8 (MS medium supplemented with 2,4-
dichlorophenoxyacetic acid (0.5 mg/L), kinetin (0.2 mg/L), 3% sucrose and 0.3% 
Phytagel). 
Cultures were kept in the growth chamber at 22 °C under 16h light and 8h dark 
conditions (white ﬂuorescent light, intensity 50 µmol m2 s-1). 
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CHAPTER 10 
RESULTS AND DISCUSSION 
10.1 QUALITATIVE ANALYSIS OF THE EXTRACTS BY GC-MS 
The alkaloid extracts obtained separately from C. angustum, P. illyricum, and L. 
nicaeense plants, were analysed by GC-MS, in order to obtain their qualitative analysis. 
In tables 10.1, 10.2, and 10.3, are reported detected alkaloids for each extract, with their 
retention time, molecular ion, and their expression in terms of TIC % (Total Ion 
Current). In all extracts have been identified different types of alkaloids, all previously 
known except for leaves extract of P. illyricum, where has been identified a compound 
with a spectrum fragmentation of alkaloid type and molecular ion of 389 [M]
+
, but not 
recognizable with available database. 
These plants have never been undergone at phytochemical screening; thus, it was 
possible to identify for each extract important alkaloids, like: galanthindole in C. 
angustum, a new alkaloid with non-fused indole ring [73], hordenine in L. nicaeense, a 
protoalkaloid, which is a side-reaction in the biosynthetic pathway of the 
Amaryllidaceae alkaloids, particularly present in vitro plant cultures [74], and new, but 
not yet known alkaloid with molecular ion 389 [M]
+
, from leaves extract of P. illyricum. 
 
10.2 QUANTITATIVE ANALYSIS OF THE EXTRACTS BY HPLC-DAD 
In tables 10.4, 10.5, and 10.6 are shown the amounts of alkaloids detected with HPLC-
DAD analysis of plant extracts. By liquid-liquid extraction, aimed at achieving only the 
alkaloid fraction of crude extracts of C. angustum, P. illyricum and L. nicaeense, were 
obtained the following extraction yields: 0.09 w/w % for C. angustum; 0.43 w/w % 
from bulbs extract of P. illyricum; 0.49 w/w % from leaves extract of P. illyricum. As 
regards L. nicaeense were obtained: 0.018 w/w % and 0.023 w/w % respectively for in 
vitro plants (Clone 1) and acclimated plants (Clone 1); 0.009 w/w % and 0.018 w/w % 
respectively for in vitro plants (Clone 2) and acclimated plants (Clone 2); 0.030 w/w % 
and 0.016 w/w % respectively for in vitro plants (Clone 4) and acclimated plants (Clone 
4). The amount detected in the extracts follows the % of TIC expressed by qualitative 
analysis. An important point regards the different extracts of L. nicaeense. In fact, the 
amount of hordenine and anhydrolycorine changes depending on whether are evaluated 
the extracts from in vitro plants or the extracts from acclimated plants. In the specific  
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case, hordenine is the principal alkaloid in the extracts from in vitro plants, while in the 
acclimated plant extracts the principal alkaloid is the anhydrolycorine. Furthermore, if  
in vitro plant extracts, galanthamine there is only in trace, in acclimated plant extracts is 
possible to quantify. 
According to reports by Berkov et al. (2010), hordenine is a protoalkaloid, and 
represents a predominant alkaloid in undifferentiated calli. Passing from plant grown in 
vitro to that grown in nature, the amount of protoalkaloids decreases in favor of the 
alkaloids, until reach the production of more complex alkaloids only in highly 
differentiated plant tissues, that is, leaves and bulbs. 
In the present case have been treated micropropagated plants, some of which have been 
maintained in vitro and other acclimatized in the greenhouse. In both cases these plants 
derived from in vitro cultures, and this probably justifies the low difference in the 
alkaloid amounts in extracts of L. nicaeense. Regarding clones analyzed (Clone 1, 2, 4), 
there they are not significant differences in the total content of alkaloids. 
For this reason was chosen of the total six samples of L. nicaeense only one sample (in 
vitro plant of Clone 4), to be subjected to subsequent pharmacological activity assays. 
This sample was the one to give greater extraction yield; when in this work will be 
referenced to the extract of L. nicaeense will be considered the extract obtained from in 
vitro plants of the Clone 4. 
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Table 10.1 Qualitative analysis by GC-MS of C. angustum extract. 
Values are expressed as % of TIC (Total Ion Current) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.2 Qualitative analysis by GC-MS in the P. illyricum extracts. 
Values are expressed as % of TIC (Total Ion Current) 
 
Alkaloid Rt  [M]+ Bulbs Leaves 
Galanthamine 21,61  287 7,56 Tr 
Sanguinine 21,88  273 6,54 0,92 
Vittatine 22,91  271 10,49 17,59 
Habranthine 23,78  303 3,05  
Lycorine 26,96  276 24,35 38,86 
Leucotamine 28,76  359  13,69 
O-Methylleucotamine 28,88  373  20,95 
2-Hydroxyhomolycorine 29,83  125 49,3 0,68 
11α-hydroxy-O-methylleucotamine 30,75  389  3,36 
 
Table 10.3 Qualitative analysis by GC-MS of L.nicaeense extracts. 
Values are expressed as % of TIC (Total Ion Current) 
 
Alkaloid Rt [M]+  
Vitro 
Clone 
1 
Acclimated 
Clone 1 
Vitro 
Clone 
2 
Acclimated 
Clone 2 
Vitro 
Clone 
4 
Acclimated 
Clone 4 
Hordenine 6,47 165  70,49 40,32 71,56 40,11 70,71 40,77 
Galanthamine 21,61 287  tr 5,89 tr 7,34 tr tr 
Anhydrolycorine 23,90 251  28,22 54,20 27,94 51,25 28,78 51,97 
 
Alkaloid Rt  [M]+ 
Whole 
plant 
Extract 
Ismine 19,62  257 7,26 
 Trisphaeridine 19,59  223 1,24 
 5,6-Dihydrobicolorine 20,56  238 4,11 
 Galanthamine 21,56  286 5,19 
 N-Demethylgalanthamine 22,25  272 28,14 
 Vittatine 22,81  271 1,28 
 Galanthindole 23,19  281 30,18 
 Crinamine 25,38  272 1,30 
 Lycorine 26,81  276 20,98 
 N-Formylnorgalanthamine 27,54  301 5,03 
 Macronine 27,90  299 18,01 
 48 
 
Table 10.4 Quantitative analysis in C. angustum extract byHPLC-DAD. 
Values are expressed as mg of compound / g of FW 
For each extract value represents the mean ± standard deviation of three independent 
determinations by HPLC analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.5 Quantitative analysis in P. illyricum extract by HPLC-DAD. Values are expressed 
as mg of compound / g of FW 
Alkaloid 
Bulbs 
mg/g FW 
Leaves 
mg/g 
FW 
Galanthamine 30,80 ± 1,1 Tr 
Sanguinine 25,90  ±0,7 4,40 ± 0,9 
Vittatine 39,69 ± 1,4 83,30 ± 1,1 
Habranthine 14,45 ± 0,9 Tr 
Lycorine 105,29 ± 1,2 184,00 ± 1,1 
Leucotamine  64,80 ± 1,2 
O-Methylleucotamine  99,50 ± 1,4 
2-Hydroxyhomolycorine 222,88 ± 1,7 3,20 ± 1,4 
11α-hydroxy-O-methylleucotamine  15,90 ± 1,2 
 
 
Table 10.6 Quantitative analysis in L. nicaeense extract by HPLC-DAD. 
Values are expressed as mg of compound/g of FW 
Alkaloid 
Vitro 
Clone 1 
mg/g FW 
Acclimated 
Clone 1 
mg/g FW 
Vitro 
Clone 2 
mg/g FW 
Acclimated 
Clone 2 
mg/g FW 
Vitro 
Clone 4 
mg/g FW 
Acclimated 
Clone 4 
mg/g FW 
Hordenine 15 ± 1,1 9 ± 0,5 7 ± 0,5 4 ± 0,3 20 ± 0,4 3 ± 0,7 
Galanthamine tr 4 ± 0,9 Tr 5 ± 0,7 tr 5 ± 0,6 
Anhydrolycorine 3 ± 0,3 11 ± 0,2 2 ± 0,2 9 ± 0,2 10 ± 0,1 8 ± 0,3 
Alkaloid mg/g FW 
Ismine 6,26 ± 1,2 
 Trisphaeridine 1,74 ± 0,2 
 5,6-Dihydrobicolorine 5,78 ± 0,9 
 Galanthamine 5,61 ± 0,7 
 N-Demethylgalanthamine 12,43 ± 1,1 
 Vittatine 8,39 ± 0,9 
 Galanthindole 32,13 ± 1,3 
 Crinamine 1,83 ± 0,05 
 Lycorine 20,09 ± 0,6 
 N-Formylnorgalanthamine 6,04 ± 0,7 
 Macronine 2,09 ± 0,3 
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10.3 ONE AND TWO-DIMENSIONAL NMR CHARACTERIZATION OF THE 
NEW ALKALOID 11α-HYDROXY-O-METHYLLEUCOTAMINE BY P. 
ILLYRICUM EXTRACT 
The results of GC-MS analysis of the leaves extract of P. illyricum has detected the 
presence of a compound with spectrum fragmentation of alkaloid type but not 
identifiable by database. The identification of this compound and the structural 
elucidation were attained through the combined use of GC–MS, HRMS, and one and 
two-dimensional NMR techniques. The HRMS of the unknown compound suggested a 
molecular formula C21H28NO6 for [M + H]
+
 with a parent ion at m/z 390.1922 (calc. 
390.1911). The EIMS showed a molecular ion [M]
+
 at m/z 389 (15.0%) with a base 
peak at m/z 286. This value evidenced the loss of the butyryl group at C-3, in 
accordance with the mass fragmentation of other alkaloids with the same kind of 
substituent group [75]. The IR spectrum showed absorption of hydroxyl (3429 cm
-1
), 
ester (1725 cm
-1
), and olefin (1624 cm
-1
) groups. The 
1
H NMR of the new compound 
was very similar to that of O-methylleucotamine, isolated for the first time from 
Leucojum aestivum leaves [76], with some differences in the chemical shifts of H-11ß, 
H-6ß and H-1. A comparison of the chemical shifts of the proton in position H-11ß of 
O-methylleucotamine and the new molecule revealed that H-11ß is more deshielded in 
the latter (d 3.46) than in the former (d 2.14). This may be due to the presence, in the 
new compound, of an interaction with a more electronegative group, which, on the 
contrary, was not present in O-methylleucotamine. The difference between two 
compounds in terms of molecular weight suggests the presence of a hydroxyl group. 
The α-position for the hydroxyl substituent is assigned by the small coupling constant J 
(11ß,12ß) = 4.7 Hz, which suggests a cis relationship between H-11ß and H-12ß and, 
consequently, the α-position for the hydroxyl substituent. The elucidation of 2D NMR 
(
1
H-
1
H COSY, NOESY and HMBC) spectra confirmed this hypothesis and allowed to 
identify the key for the exact identification of the new molecule. By data obtained with 
the nuclear magnetic resonance techniques, has been classified new compound as 11α-
hydroxy-O-methylleucotamine. In figure 10.1 is shown the structure of the new 
compound. 
1
H NMR spectrum of the 11α-hydroxy-O-methylleucotamine is reported in 
figure 10.2. The complete assignment of NMR data for 11α-hydroxy-O-
methylleucotamine is presented in table 10.7. 
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Fig. 10.1 Structure of the new compound 11α-hydroxy-O-methylleucotamine isolated from 
leaves extract of P. illyricum L. 
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Fig. 10.2 
1H NMR spectrum of 11α-hydroxy-O-methylleucotamine 
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Table 10.7 
 1
H-NMR, 
13
C-NMR, COSY, NOESY and HMBC data of 11α-hydroxy-O-
methylleucotamine 
Position 
1
H δ (J in Hz) COSY NOESY 13C δ HMBC 
1 5.28 td (3.1, 1.0) 
H-2α, H-2β, H-4a, 
H-4 
H-2α, H-2β, H-11β 81.1 C-3, C-4a, C-10b, C-11 
2α 
2.10 ddd (16.5, 5.3, 
3.2) 
H-1, H-2β, H-3 H-1, H-2β, H-3, H-11β 
27.4 
 
2β 
2.71 ddt (16.5, 3.1, 
1.5) 
H-1, H-2α, H-3, H-4 H-1, H-2α, H-3 C-1, C-3, C-4, C-10b 
3 5.37 br t (5.0) 
H-2α, H-2β, H-4, H-
4° 
H-2α, H-2β, H-4 63.3 C-1, C-2, C-4, C-4a, CO 
4 
5.94 ddd (10.3, 5.0, 
1.2) 
H-2β, H-3, H-4a, H-
1 
H-3, H-4a 124.8 C-2, C-3, C-10b 
4a 6.05 dt (10.3, 1.0) H-1, H-3, H-4 H-4, H-6β, H-12β 130.1 
C-1, C-3, C-4, C-10a, C-
10b 
6α 3.57 dd (14.6, 1.5) H-6β, H-12α H-6β, H-7, NMe 
63.0 
C-7, C-10a, C-12, NMe 
6β 3.76 d (14.6) H-6α, H-7 
H-4a, H-6α H-12β, 
NMe 
C-6a, C-7, C-10a, C-12 
6°    147.9  
7 6.55 d (8.2) H-6α, H-6β, H-8 H-6α, H-8 120.6 C-6, C-6a, C-9, C-10° 
8 6.67 d (8.2) H-6β, H-7, OMe H-7, OMe 111.8 C-6a, C-7, C-9, C-10 
9    144.2  
10    128.7  
10a    128.2  
10b    54.0  
11β 3.46 d (4.7) H-12β H-1, H-2α, H-12β 67.7 C-1, C-10a, C-10b 
12α 
3.06 ddd (13.3, 4.9, 
1.6) 
H-6α, H-11β, H-12β H-11β, NMe 
61.2 C-6, C-10b, C-11 NMe 
12β 3.11 d (13.1) H-12α 
H-4a, H-6β, H-11β, 
NMe 
OMe 3.84 s H-8 H-8, H4´ 56.1 C-9 
NMe 2.57 s  
H-6α, H-6β, H-12α, H-
12β 
49.5 C-6, C-12 
CO    172.1  
2’a 2.49 dd (16.2, 3.1) H-2´b, H-3’ H-2´b, H-3’, H-4’ 
43.9 C-3’, C-4’, CO 
2’b 2.39 dd (16.2, 9.4) H-2´a, H-3’ H-2´a, H-3’, H-4’ 
3’ 
4.19 dqd (9.5, 6.3, 
3.1) 
H-2’a, H-2’b, H-4’ H-2’a, H-2’b, H-4’ 64.1  
4’ (3H) 1.19 d (6.3) H-3’ H-2’, H-3’, OMe 22.7 C-2’, C-3’, CO 
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10.4 CYTOTOXICITY 
The cytotoxicity assays were carried out on alkaloid extracts of C. angustum, P. 
illyricum and L. nicaeense for 24h. After exposure of human embryo lung fibroblast 
with the extracts, was observed only a moderate decrease in cell viability, considering a 
wide range of concentrations: from 0.625 mg/mL to 0.078 mg/mL.  
Initially was considered the reduction of viability due to the solvent used, in this case 
DMSO. Considering the lack of cell viability inhibition given from DMSO, as a positive 
control were selected untreated cells. Figure 10.3, 10.4, 10.5, respectively show % of 
vitality of each extract compared to positive control and solvent 
For each extract was calculated the relative concentration (compared to control 
considered to 100% of vitality) that reduces to 20% cell viability. Is important to 
consider that the concentrations used of three extracts in the assays reported in this 
work, were been always below the cytotoxic concentrations. 
Concentration that reduces to 20% cell viability for each extract: For C. angustum, P. 
illyricum and L. nicaeense extracts, values of cell vitality inhibition are greater than 
0.625 mg/mL. 
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Fig. 10.3 Cell viability of C. angustum extract. 
The graph shows the optical density (OD) that represent the vitality of cells, after cell exposure 
with increasing concentrations of C. angustum extract for 24h compared to control cells. 
 
 
 
Fig. 10.4 Cell viability of bulbs and leaves extract of P. illyricum. 
The graph shows the optical density (OD) that represent the vitality of cells, after cell exposure 
with increasing concentrations of bulbs and leaves P. illyricum extract for 24h compared to 
control cells. 
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Fig. 10.5 Cell viability of L. nicaeense extract. 
The graph shows the optical density (OD) that represent the vitality of cells, after cell exposure 
with increasing concentrations of L. nicaeense extract for 24h compared to control cells. 
 
 
 
10.5 ANTIOXIDANT ACTIVITY 
The alkaloid extracts of C. angustum, P. illyricum and L. nicaeense, were tested with different 
antioxidant assays in order to assess the potential multiple action to prevent the 
formation and to remove reactive species. 
All three alkaloid extracts have not shown activity against antioxidant assays that 
involved radical species derived from 2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic 
acid) ABTS and 2,2-diphenyl-1-picrylhydrazyl (DPPH). This occurs because the main 
method of shutting down the radical in this assay is given by transferring of a hydrogen 
atom or an electron on radical. The examined extracts probably possess stable 
molecules that do not provide elements capable to altering the radical formed in the 
assay. 
Regarding the β-Carotene bleaching assay, a common method for evaluating the 
inhibition of lipid peroxidation, was shown again the low ability of the extracts to act as 
a scavenger. However, while in the ABTS and DPPH assays was not possible to obtain 
a measurable result, here was possible to carry out a measurement and could be 
identified in the extract of C. angustum, with an IC50 of 31.54 µg/mL, a higher  
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protection activity than other analyzed extracts. In table 10.8 are reported IC50 values 
and the relative TEAC values of the extracts for β-Carotene bleaching assay. 
Considering that also in this assay is basically implicated the mechanism of donation of 
a hydrogen, higher reactivity compared to the ABTS and DPPH assay may be due to the 
fact that in a lipid emulsion, reaction environment of this assay, the hydrophobic 
repulsion phenomena favor the activity of apolar compounds against the polar ones 
[77]. 
 
 
 
 
Table 10.8 Antioxidant activity of C. angustum, P. illyricum and L. nicaeense extracts by β-
Carotene Bleaching test. Data are expressed as IC50 values (µg/mL) for extracts and also in µM 
for the reference compound (Trolox). For a direct comparison, values are expressed also in 
TEAC (Trolox Equivalent Antioxidant Capacity). Results are means ±SD of three independent 
experiments with three replicates. 
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10.6 ENZYMATIC INHIBITION ACTIVITY 
10.6.1 ACETYLCHOLINESTERASE INHIBITION 
Is well known that the Amaryllidaceae alkaloids are an excellent sources of molecules 
with inhibitory activity against the Acetylcholinesterase enzyme. The extracts of C. 
angustum, P. illyricum and L. nicaeense were tested. In addition, considering that the 
new compound isolated from the leaves extract of Pancratium illyricum is galanthamine 
type, has been tested in order to carry out a direct comparison with the reference 
standard galanthamine hydrobromide. 
The extracts of C. angustum and L. nicaeense showed no activity, probably because the 
alkaloids in higher concentrations present in these extracts are not of galanthamine type, 
and in addition to not having activity prevent the action of the active alkaloids. 
The extracts of bulbs and leaves of P. illyricum, respectively showed an IC50 of 244  
1.1 µg/mL and 166  1.7 µg/mL. 
Considering the activity of standard and the isolated compound, can see that the activity 
of the 11α-hydroxy-O-methylleucotamine shows no significant difference with that of 
galanthamine hydrobromide. The IC50 for each compounds are: 3.5 ± 1.1 µM for 11α-
hydroxy-O-methylleucotamine, and 1.5 ± 0.2 µM for galanthamine hydrobromide. In 
figure 10.6 is shown dose-response curve of the inhibition of AChE enzyme both for 
reference standard and the new compound. In table 10.9 in order to make a comparison 
of inhibition capacity of extracts and pure compounds, values are expressed in µg/mL. 
In an AChE inhibition screening of several Amaryllidaceae alkaloids from the genus 
Narcissus, the most active natural alkaloid (ca. 10 times higher than galanthamine) 
turned out to be sanguinine [78]. This compound showed, compared with galanthamine, 
a hydroxyl group at C-9 instead of a methoxyl group. An in vitro structure–activity 
relationship investigation indicates that hydrophilic groups opportunely placed on 
galanthamine contribute to its effective binding to the enzyme [79]. In the same way, a 
different spatial orientation of a hydrophilic substituent may increase or decrease 
interactions within the active site of AChE. For instance, the ß-configuration of the 
hydroxyl group at position 11 of 11ß-hydroxygalanthamine decreases by 10 times the 
enzymeactivity compared to its epimer habranthine. 11α-hydroxy-O-
methylleucotamine, obtained here from P. illyricum, showed a slightly lower activity 
than 11α-hydroxygalanthamine (IC 50 = 1.61 ± 0.2), probably due to the presence of the  
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bulky butyryl group at C-3, but it resulted more active than 11ß-hydroxygalanthamine 
[80]. Thus, theß-configuration of the hydroxyl group at position 11 could make the  
compound less amenable for interactions with the active site of AChE compared to the 
butyryl substituent in position 3. 
 
 
Fig. 10.5 Dose-response curve of the inhibition of AChE enzyme both for galanthamine 
hydrobromide and 11α-hydroxy-O-methylleucotamine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.9 Values of the inhibition of AChE enzyme for plant extracts and pure compounds 
expressed in µg/mL. 
 
Alkaloid Extract 
And Pure Compounds 
IC50 
P. illyricum bulbs 224 ± 1,1 
P. illyricum leaves 166 ±1,7 
Galanthamine 0,43 ± 0,2 
11α-hydroxy-O-methylleucotamine 1,36 ± 1,1 
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10.6.2 COLLAGENASE INHIBITION 
Two different assays were applied as regards the inhibition of collagenase enzyme. The 
first one involves use of synthetic substrate FALGPA (N-3-(2-Furyl)acryloyl-Leu-Gly-
Pro-Ala), and the second one use of a natural substrate such as collagen from bovine 
tendons. The alkaloid extracts of C. angustum, P. illyricum and L. nicaeense were tested 
using both methods. 
Analyzing the results obtained with the synthetic substrate, extracts have been shown to 
inhibit the enzyme in so far of: C. angustum extract has not inhibitory activity; P. 
illyricum has shown a different inhibitory activity regarding leaves and bulbs extract, in 
fact, at the same tested concentration of 200 µg/mL, bulbs extract showed 99.61% ± 1.2 
of inhibition and leaves extract 47.62% ± 1.6; L. nicaeense extract with 200 µg/mL has 
given an inhibition of 21.76% ± 0.9. 
Considering these data the bulbs extract of P. illyricum was chosen in order to establish 
an IC50 value and a possible mechanism of action. 
In figure 10.6 is shown the diagram of Lineweaver-Burk that demonstrates the 
mechanism of action of the extract. Variation of VMAX and KM values compared to the 
enzyme without inhibitor suggests that the inhibition of the extract on the enzyme is 
reversible and uncompetitive type. Mechanism probably is attributable to a double 
action of alkaloid extract; initially chelating Ca
2+
 ions present in the reaction, 
fundamental for the activation the enzyme, and at the same time probably interacting 
with the active site of the enzyme. In table 10.10 are listed kinetic parameters on the 
enzyme inhibition given by the bulbs extract of P. illyricum.  
The IC50 value obtained from the bulbs extract of P. illyricum is directly comparable to 
that of the reference standard epigallocatechin gallate (EGCG) in order of µg/mL. 
In table 10.11 is shown IC50 value of bulbs extract of P. illyricum, and that of the 
reference compound EGCG. 
Is noteworthy that although the bulbs and leaves extract of P. illyricum have almost the 
same qualitative composition, quantitatively alkaloids are found in opposite 
concentrations. Basically, if an alkaloids prevail in concentration into one extracts, 
decreases in the other. Moreover considering the belonging alkaloid class, in bulbs 
extract prevailing alkaloids group is lycorine, whereas in leaves extract there is a 
balance between alkaloid types. Probably the most important activity of the bulbs 
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extract than the leaves extract, could be given by the predominance of lycorine-type 
alkaloids in the former. 
In the assay which foresees the use of bovine collagen as a substrate, were tested the 
same extracts at fixed concentration of 333 µg/mL. Were also tested three pure 
compounds representing some of the main components in the examined extracts, at 
fixed concentration of 400 µM. The IC50 value of the reference standard (EGCG) in this 
assay is 360 µg/mL or expressed in molarity 785 µM. Comparing IC50 value of 
epigallocatechin gallate (IC50 4.33 µg/mL and 9.45 µM) obtain with the first method, to 
achieve the same effect of the first one, is necessary to use concentrations 10 times 
higher. 
By the extracts were obtained the following percentages of inhibition: 39.49% ± 2.0 for 
C. angustum extract, 86.37% ± 1.2 for P. illyricum bulbs extract, 83.94% ± 1.9 for P. 
illyricum leaves extract, and 56.96% ± 1.7 for L. nicaeense extract. Lycorine, Vittatine 
and Hordenine, the pure compounds tested, at the analyzed concentration have not 
shown activity. Table 10.12 shows the percentages of inhibition for extracts and 
compounds, tested in both assays of collagenase inhibition. 
Using this assay, all samples tested showed an activity, except pure compounds. One 
possible explanation for the apparent discrepancy in the inhibition values can be given 
by different reaction times and different interaction between enzyme, substrate and 
inhibitor. In the assay that uses FALGPA as substrate, reaction times is rated in 5 min; 
in the assay that uses Collagen as substrate, reaction times is rated in 5 hours; in the 
latter case, has a longer time to develop the inhibitory action or a longer time to 
neutralize the inhibitor. 
In the assay that uses FALGPA as substrate, occurs primarily an interaction between 
enzyme and inhibitor [81], in the assay with Collagen the interaction is between 
substrate and inhibitor. Essentially, samples that have no interaction with the enzyme in 
the first assay may have a greater interaction with the substrate with the second method. 
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Fig. 10.6 Lineweaver-Burk graphic: mechanism of action of the bulbs extract of P. illyricum. 
 
 
Table 10.10 Kinetic parameters on the enzyme inhibition given by the extract of P. illyricum. 
its IC50 value in µg/mL, and that of the reference compound EGCG which is expressed both in 
uM and as µg/mL. 
 
 
Table 10.11 IC50 value in µg/mL of P. illyricum bulbs, and that of the reference compound 
EGCG which is expressed both in uM and as µg/mL. 
 
 
Table 10.12 Percentage of collagenase inhibition from extracts of C. angustum, P. illyricum , L. 
nicaeense and pure compounds lycorine, vittatine and hordenine in both collagenase inhibition 
assays 
Alkaloid Extract 
And Pure Compounds 
FALGPA substrate COLLAGEN  substrate 
C. angustum no inhibition 39,49% ± 2,0 
P. Illyricum bulbs 99,61% ± 1,2 86,37% ± 1,2 
P. Illyricum leaves 47,62% ±1,6 83,94% ± 1,9 
L. nicaeense 21,76% ± 0,9 56,96% ± 1,7 
Lycorine - no inhibition 
Vittatine - no inhibition 
Hordenine - no inhibition 
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10.6.3 TYROSINASE INHIBITION 
In preliminary study the extract of C. angustum, P. illyricum, and L. nicaeense, also with three 
pure alkaloid compounds, like galanthamine, lycorine and hordenine were tested at fixed 
concentration of 250 µg/mL. Molecule used as a reference was Kojic acid, which has an 
IC50 value of 14.7 ± 2.0 µM (2.09 µg/mL). The percentages of inhibition were: C. 
angustum extract, no inhibition; bulbs extract of P. illyricum 34% ± 2.1; leaves extract 
of P. illyricum 10% ± 0.7; L. nicaeense extract 32%.± 0.2 Regarding pure compounds: 
galanthamine no inhibition, lycorine no inhibition, and hordenine 45% ± 0.5 of 
inhibition. 
Is important to note the difference in activity between the bulbs and leaves extracts of P. 
illyricum. The decrease of activity in the leaves extract could be explained by the fact 
that in this extract tend to predominate compounds as galanthamine and lycorine, that 
have shown their inactivity by testing separately. In parallel hordenine is one of the 
major compounds present in the extract of L. nicaeense, and is probably the presence of 
this molecule that confers activity to the extract, in fact tested separately showing a 
greater inhibitory activity of the extract itself. This inhibition ability of hordenine may 
be explained in terms of similarity between the dihydroxyphenyl group in L-Dopa and 
the similar group in hordenine; is also possible that the interaction with non-active 
components in the extract decreases its function. These data would be in agreement with 
recent work where hordenine is proposed like compound capable to inhibits 
melanogenesis in human melanocytes [82].  
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10.7 ANTIMICROBIAL ACTIVITY 
10.7.1 BACTERIAL AND FUNGAL GROWTH  INHIBITION ON ATCC 
STRAINS 
Extracts of C. angustum, and P. illyricum, were tested against ATCC bacterial and 
fungal strains. L. nicaeense extract has not been tested on this kind of activity; as 
obtained by in vitro material, the available amount was not enough to the realization of 
this assay. The antimicrobial activity of the extracts were evaluated against 9 standard 
strains of microorganisms, that include Staphylococcus aureus, S. epidermidis, 
Streptococcus pyogenes, Enterococcus faecalis, Klebsiella pneumoniae, Escherichia 
coli, Pseudomonas aeruginosa, Proteus mirabilis and Candida albicans.  
The alkaloid extract of C. angustum was found to be more active on Gram-positive 
bacterial strains (S. aureus, S. epidermidis, S. pyogenes, E. faecalis) than on Gram-
negative ones (E. coli, K. pneumoniae, P. aeruginosa, P. mirabilis), with IC50 values 
ranging from 156 to 625 µg/mL after 8 h incubation. Among Gram-negative bacterial 
strains, an inhibitory activity was observed only on K. pneumoniae at 8 h incubation. It 
is noteworthy to observe that a pronounced activity (IC50 78 μg/mL) against C. albicans 
was found at 24 and 48 h incubation. Based on the chemical structure of the molecules 
present in the extract and the biological activities reported for these compounds, an 
hypothesis can be put forward regarding the major candidates responsible for the 
antimicrobial activity. As regards lycorine, previous reports demonstrated the lack of 
inhibitory effect of this alkaloid on the growth of S. aureus, E. coli, and P. aeruginosa, 
while showing an excellent antifungal activity on C. albicans [13] Our results indicate 
that Crinum alkaloid extract did not show any antibacterial activity on E. coli and P. 
aeruginosa, showed only a low activity on S. aureus (IC50 1.25 mg/ml after 24 h 
incubation), while having a good antifungal activity on C. albicans. This can be 
explained by the fact that both S. aureus and P. aeruginosa  are able to transform 
lycorine into its inactive metabolite 2-O-demethylungiminorine, instead of the active 
ungeremine [83]. Since a stimulatory effect on bacterial growth has been reported for 2-
O-demethylungiminorine, this can explain, in part, the lack of antimicrobial activity of 
the alkaloid extract on S. aureus. The alkaloids of galanthamine-, narciclasine-, 
tazettine- and haemanthamine-type were also present in C. angustum alkaloid extract.  
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As regards alkaloids belonging to the first three types, no antibacterial or antifungal 
activities have hitherto been reported, even though a wide array of biological activities  
have been demonstrated [84]. As regards alkaloids of the haemanthamine-type, 
represented in this specific case by vittatine and crinamine, an antibacterial activity was 
demonstrated on S. aureus and C. albicans. As showed by Evidente et al., (2004), 
vittatine was reported to be active against these strains (MIC values of 63 and 31 
µg/mL, respectively), and an inhibitory activity against S. aureus was found for 
crinamine [85]. Thus, considering the results here obtained on Crinum alkaloid extract 
and data from previous studies on purified alkaloids, it is likely that vittatine and 
crinamine did play a role in the antimicrobial activity of the extract. Besides these, also 
galanthindole might contribute to the inhibitory activity. Indeed, the presence of an 
indole group within this molecule can support this hypothesis, since a key role for this 
important heterocyclic system in several biologically active molecules exhibiting 
antimicrobial and antifungal capacity has been reported [86].  
It is worth noting that quite often the activity found for the total alkaloid extract is lower 
than that of pure components, as a consequence of the fact that pure compounds are 
highly selective in their interaction with the bacterial pathogens [87], thus being 
attenuated in their potency when mixed with other components in a total extract. 
Table 10.13 shows the complete values of C. angustum extract at 8h and 24h of 
incubation with the corresponding reference standard gentamicin. 
As regard P. illyricum extract, showed no significant activity against bacterial ATCC 
strains, while it proved particularly active against Candida albicans, with IC50 values of 
39 µg/mL for bulbs extract and 78 µg/mL for leaves extract at 24h of incubation. The 
extract of bulbs and leaves of P. illyricum were also tested with C. albicans strain until 
48h of incubation, obtaining respectively IC50 values of 78 µg/mL and 156 µg/mL. 
Analyzing the alkaloids found in these extracts, to light of the foregoing, can be 
attributed the absence of activity against bacterial strains at the preponderant presence in 
the extracts of the alkaloids lycorine and galanthamine type; the former are transformed 
into inactive metabolites by S. aureus, and the latter do not have antibacterial activity. 
Rather lycorine-type alkaloids are an excellent antifungal activity, probably for this 
reason, in bulbs where they are in greater quantity than that in leaves, is shown 
increased antifungal activity.  
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Considering the good activity shown on this Candida species, is thought to test bulbs 
and leaves extract of P. illyricum, on three different Candida species responsible for 
nosocomial infections. 
Thus, have been tested: C. parapsilosis, C. tropicalis, and C. glabrata, at 24-48h of 
incubation. The IC50 values achieved are comparable with those obtained for the C 
albicans at 24h incubation. Regarding the C. parapsilosis, bulbs activity is higher than 
in leaves, but constant in both at 24 and 48h. C. tropicalis . resistance is greater than the 
other Candida species, but with constant values both in bulbs and leaves extract. C. 
glabrata, possesses values of inhibition comparable with C parapsilosis and C. albicans 
only to 24h. C. albicans, shows IC50 values comparable to those shown in C. 
parapsilosis; even in this case bulbs possess better inhibitory activity. 
In table 10.14 are shown IC50 values at 24 and 48 h of incubation, and the relative 
reference standard Amphotericin, for the four Candida species analyzed with bulbs and 
leaves extract of P. illyricum  
 
Table 10.13 Complete values of C. angustum extract at 8h and 24h of incubation on microbial 
ATCC strains with the corresponding reference standard gentamicin. 
Microorganism 
IC50 (8h-incubation) 
(g/mL) 
IC50 (24h-incubation) 
(g/mL) 
Positive control  
IC50 24h (g/mL)  
S. aureus 
S. epidermidis 
S. pyogenes 
E. faecalis 
E. coli 
K. pneumoniae 
P. aeruginosa 
P. mirabilis 
C. albicans* 
312 ± 1,4 
156 ± 1,1 
312 ± 1,9 
625 ± 2,0 
- 
625 ± 2,0 
- 
- 
no growth 
1250 ± 3,4 
625 ± 1,8 
312 ± 1,4 
- 
- 
- 
- 
- 
78 ± 1,5(48 h: 78) 
1.0 ± 0,01 
2.0 ± 0,01 
4.0 ± 0,02 
4.0 ± 0,02 
4.0 ± 0,03 
4.0 ± 0,02 
8.0 ± 0,02 
4.0 ± 0,03 
2.0 ± 0,02 
:- no inhibition. * IC50 values for C. albicans ATCC 10231 were determined after 48 h 
incubation and Positive Control was nystatin 
 
 
 
 
 
 65 
 
 
Table 10.14 Complete values of P. illyricum bulbs and leaves extract at 24h and 48h of 
incubation on Candida ATCC strains with the corresponding reference standard Amphotericin 
 
Bulbs extract of  
P. Illyricum 
Leaves extract of 
P. illyricum 
Positive Control 
Amphotericin IC50 
(µg/mL) 
IC50 24h 
(µg/mL) 
IC50 48h 
(µg/mL) 
IC50 24h 
(µg/mL) 
IC50 48h 
(µg/mL) 
C. parapsilosis 39 ± 0,2 39 ± 0,3 78 ± 0,4 78 ± 0,4 2,0 ± 0,01 
C. tropicalis 156 ± 0,6 310 ± 1,3 156 ± 0,6 310 ± 1,2 4,0 ± 0,03 
C. glabrata 39 ± 0,4 156 ± 0,4 78 ± 0,4 310 ± 1,4 4,0 ± 0,03 
C. albicans 39 ± 0,2 78 ± 0,2 78 ± 0,6 156 ± 0,8 4,0 ± 0,02 
 
 
10.7.2 BACTERIAL AND FUNGAL GROWTH INHIBITION ON CLINICAL 
ISOLATES 
Considering the promising inhibitory activity of the extracts of C. angustum and P. 
illyricum against different ATCC strains, both bacterial and fungal type, was carried out 
a direct analysis on clinical isolates. 
As regards the C. angustum, was tested clinical isolates of methicillin-resistant S. 
aureus (MRSA) and carbapenemase-producing Klebsiella pneumoniae (KPCs). Were 
chosen these bacteria, as, the former is the main source of clinically significant 
infections; the latter is one of the most resistant gram negative bacteria, the only one 
wherein the C. angustum extract showed a good inhibitory activity at 8h of incubation. 
Tests were carried out both at 8 and 24h of incubation, and the results showed that: 
KPCs ones were inhibited by the C. angustum extract only at 8h of incubation with a 
IC50 range between 312 and 625 µg/mL, while a bacteriostatic effect was found against 
the MRSA isolates with IC50 values ranging from 156 to 1250 µg/mL. 
These data are consistent with those obtained on the ATCC strains, and are not 
significantly different between them, whereas that patients from which come represent 
different clinical cases. 
Table 10.15 shows the IC50 of the C. angustum extract at 8 and 24h of incubation on 
MRSA and KPCS clinical isolates. 
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As regards P. illyricum were tested C. albicans clinical isolates, as, this species is a 
major cause of nosocomial infections. Furthermore, whereas it in ATCC strains the 
extract to having increased activity was bulbs extract, and considering that this extract  
contains lycorine, alkaloid which has been given high antifungal activity, as reported in 
Evidente et al., (2004), on clinical isolates were tested: bulbs extract of P. illyricum, 
Lycorine, and reference standard Amphotericin, considering only 24h of incubation as 
shown in European guidelines EUCAST (European Committee for susceptibility to 
antifungal drugs) [88]. 
Whereas it isolates derived from patients with different clinical histories, there are no 
meaningful significant differences, except to clinical isolate derived from patient g, 
where the activity of bulbs extract, lycorine and the reference standard, are more 
pronounced compared to the other isolated. 
By comparing IC50 values of bulbs extract of P. illyricum and then the purified 
compound lycorine, higher inhibitory activity is exhibited by lycorina in agreement with 
reported by Cheesman et al. (2012) In fact, often the activity found for the total alkaloid 
extract is lower than that of pure components, as a consequence of the fact that pure 
compounds are highly selective in their interaction with the bacterial pathogens. 
By averaging the IC50 values obtained to clinical isolated, is possible to establish that for 
bulbs extract of P. illyricum IC50 value is 39 µg/mL, while for the purified compound 
lycorine IC50 value is 7 µg/mL. 
Table 10.16 shows complete IC50 values on the Clinical Isolates of C. albicans by P.illyricum 
bulbs extract, lycorine and reference standard Amphotericin. 
 
 
 
 
 
 
 
 
 
 
 67 
 
Table 10.15 IC50 values on the Clinical Isolates of C. angustum extract. 
Microorganism IC50 (8h-incubation) 
(g/mL) 
IC50 (24h-incubation) 
(g/mL) 
S. aureus, methicillin resistant (MRSA) 
a
 
 
S. aureus, methicillin resistant (MRSA) 
b
 
 
S. aureus, methicillin resistant (MRSA) 
c
 
 
S. aureus, methicillin resistant (MRSA) 
d
 
 
S. aureus, methicillin resistant (MRSA) 
e
 
 
S. aureus, methicillin resistant (MRSA) 
f
 
 
S. aureus, methicillin resistant (MRSA) 
g 
 
K. pneumoniae carbapenem resistant (KPC) 
1
 
 
K. pneumoniae carbapenem resistant (KPC) 
2
 
 
K. pneumoniae carbapenem resistant (KPC) 
3
 
625 ± 2,4 
 
625 ± 2,2 
 
312 ± 2,2 
 
312 ± 2,1 
 
78 ± 1,4 
 
312 ± 1,9 
 
156 ± 1,3 
 
312 ± 2,2 
 
625 ± 2,4 
 
- 
 
625 ± 2,0 
 
1250 ± 3,0 
 
1250 ± 3,1 
 
625 ± 2,2 
 
156 ± 1,4 
 
625 ± 2,2 
 
625 ± 2,0 
 
- 
 
- 
 
- 
Notes: - : No inhibition; Letters and numbers in superscripts indicate clinical isolates from 
different patients. 
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Table 10.16 IC50 values on the Clinical Isolates of C. albicans by P.illyricum bulbs extract, 
lycorine and reference standard amphotericin. Letters in superscripts indicate clinical isolates 
from different patients 
 Bulbs extract of 
P. illyricum 
IC50 (µg/mL) 24h of 
incubation  
Lycorine 
IC50 (µg/mL) 24h of 
incubation  
Positive Control Amphotericin IC50 
(µg/mL) 24h of incubation 
C. 
albicans
a 39± 0,3  7 ± 0,3  0,10 ± 0,001 
C. 
albicans
b 78 ± 0,3  10 ± 0,4  0,15 ± 0,001 
C. 
albicans
c 39 ± 0,2  8 ± 0,4  0,10 ± 0,01 
C. 
albicans
d 10 ± 0,2  4 ± 0,3  0,05 ± 0,01 
C. 
albicans
e
 
19 ± 0,2  4 ± 0,2  0,14 ± 0,02 
C. 
albicans
f
 
10 ± 0,3  4 ± 0,3  0,03 ± 0,03 
C. 
albicans
g
 
0,61 ± 0,01  0,9 ± 0,01  0,03 ± 0,001 
C. 
albicans
i
 
3 ± 0,03  0,9 ± 0,01  0,06 ± 0,002 
C. 
albicans
d
 
39 ± 0,2  7 ± 0,2  0,08 ± 0,002 
C. 
albicans
l
 
39 ± 0,2  7 ± 0,2  0,15 ± 0,001 
C. 
albicans
m
 
39 ± 0,1  7 ± 0,3  0,15 ± 0,001 
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10.8 IN VITRO DEVELOPMENT OF PLANT CELL CULTURES FROM C. 
ANGUSTUM, P. ILLYRICUM, L. NICAEENSE 
 
Were realized vegetal explants from immature fruits of C. angustum and P. illyricum for 
in vitro development of plant cell cultures. As regards L. nicaeense have been 
developed subcultures from micropropagated plants produced in CRA Center of 
Sanremo. 
The explants obtained from C. angustum have proved to be completely refractories to 
the development of callus; by subjecting the explants to different types of culture media, 
like: culture media for callus development (MS8), for organogenesis development 
(MSL), and for shoots regeneration (MSC); the explants have never led to the 
production of in vitro cell cultures. 
P .illyricum explants, subjected to growth in a medium that favored callus formation, 
has been quiescent nearly a year, then, has led to the development of very slow-growing 
calli. The lack of friability in the P. illyricum calli, has not allowed development in 
bioreactors. Transferring calli in an organogenetic culture medium used for L. nicaeense 
(IBA medium), were obtained plants can undergo to in vitro micropropagation. 
Figure 10.6 shows some of the calli samples obtained from P. illyricum. 
Regarding micropropagated plants of L. nicaeense, were subjected to cycles of 
micropropagation until to obtain a quantity that allowed phytochimical and biological 
analysis. 
Figure 10.7 shows a representative sample of micropropagated plants obtained from L. 
nicaeense. 
Results obtained as regards in vitro development of these plants, are consistent with 
those reported in the scientific works, in fact, in vitro development of plants belonging 
to the Amaryllidaceae family, occurs always through the slow formation of shoots or 
regenerated plants, as is shown in Berkov et al. (2010). 
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Fig. 10.6 Calli samples obtained from P. illyricum. 
 
 
 
 
 
Fig. 10.7 Sample of micropropagated plants obtained from L. nicaeense. 
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CONCLUSIONS 
 
In the present study were analyzed extracts enriched in alkaloids obtained from three 
different plants of the Amaryllidaceae family. In particular were investigated the plant 
extracts of: Crinum angustum, Pancratium illyricum, and Leucojum nicaeense. 
Is known as the plants, and in the specific, those belonging to this family, are sources of 
numerous molecules with important pharmacological activities for man. For this reason 
the extracts obtained were analyzed to phytochemical analysis, with a view to isolate 
novel compounds with pharmacological property, and were tested on a wide range of 
biological activities with the aim of identifying the one to which better suited. 
 
Phytochemical analysis has allowed to isolate and characterize a new molecule of 
galanthamine type from the leaves extract of P. illyricum.. This compound, 11α-
hydroxy-O-methylleucotamine, has been tested in the inhibition assay of the 
Acetylcholinesterase enzyme (AChE), and showed inhibitory activity equivalent to that 
of the molecule commercially (galanthamine) for treatment of Alzheimer disease 
symptoms. 11α-hydroxy-O-methylleucotamine could be a new compound to use in 
symptoms of this disease. 
 
Data derived from the antioxidant assays, highlight that the extracts tested do not 
possess antioxidant activity. However is important to emphasize the fact that the 
extracts were undergone in assays to involve transfer of electrons or hydrogen ions, and 
molecules present in these plant extracts do not possess this capacity. Likely using the 
extracts of C. angustum, P. illyricum and L. nicaeense, in enzymatic assays, as 
antioxidants with indirect action, where many factors are involved, not only the role of 
neutralization relate to reactive oxygen species, or considering the protective role of 
these extracts on substrates attacked by radical species, these extracts could provide 
antioxidant activity. 
 
Identify compounds which possess activity against enzymes involved in several 
diseases could be an important field of study, as, a single compound could be interested 
in treatment of different pathologies, and probably at the same time treating a disease  
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could be prevent other. For this reason was decided to test the extracts of C. angustum, 
P. illyricum and L. nicaeense against collagenase, enzyme belonging to the matrix 
metalloproteinase family, a class involved in both physiological and pathological 
processes. Of all matrix metalloproteinase, collagenase, is surely that less specific for 
certain pathologies; however, at the same time, allows to perform a screening of 
compounds potentially active in this class of enzymes. Therefore the extracts were 
tested against the collagenase enzyme with two different assays, where were employed 
two different substrates. In the first one was used synthetic substrate (FALGPA), while 
in the second one was used a natural substrate (collagen from bovine tendon). In both 
assays the most promising extract has been the P. illyricum bulbs extract, with an IC50 
value comparable to that of the positive control, epigallocatechin gallate (EGCG). 
Through the mechanism of action studied by the first essay, can be assumed for P. 
illyricum bulbs extract a double action on the enzyme; Ca
2+
chelation in the reaction 
environment fundamental to functionality of the enzyme, and an interaction with the 
active site of the enzyme. Even if these are preliminary studies, and much more can be 
done, both, to study the mechanism of action of this extract, that to study detailed the 
individual classes of matrix metalloproteinase, the obtained results allow to identify a 
group of molecules, alkaloids, as possible compounds of interested in the study of this 
wide and complex class of enzymes. In addition, the preliminary data obtained with the 
second test have confirmed the strong inhibitory activity of the bulbs extract of P. 
illyricum, has revealed the activity of L. nicaeense extract (56.96% of inhibition) not 
detected by the first assay, and has allowed to discriminate the activity of certain 
molecules in the extracts, excluding amongst the pure compounds hypothetically 
responsible for the inhibition, as: lycorine, vittatine and hordenine. 
 
As regards the tyrosinase enzyme, also known as polyphenol oxidase (PPO), 
preliminary data obtained with enzymatic assay, allows to identify rather than an extract 
and consequently a plant as a possible candidate for the inhibition of this enzyme, a 
class of pure compounds. In fact, comparing the activity shown by the extracts and by 
the purified molecules, that make up a large part of the extracts, it can be concluded 
that: hordenine has good inhibitory activity, and given the lack of activity of lycorine, 
the former is what gives activity to the extract of L. nicaeense. Considering the lack of 
activity given by lycorine and galanthamine, and the activity shown by the extracts of P. 
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illyricum (34% bulbs extract and 10% leaves extract), can say that: where prevail 
compounds lycorine and galanthamine type, there isn’t inhibitory activity, as occurs for 
example in the leaves extract of P.illyricum where these two classes of alkaloids are in 
balance; in bulbs extract of P. illyricum, where is present in large amounts a third class 
of alkaloids, or rather homolycorine type, the extract showed good inhibitory activity. 
Basically, there are two molecules in the tested extracts, which are good candidates for 
inhibition of the enzyme tyrosinase: hordenine compound and alkaloids homolycorine 
type. The importance of finding molecules able to inhibit this enzyme covers different 
fields, those where the tyrosinase plays a key role: development of melanoma, skin 
browning, and last but not least the molting in the insects in the agrochemical business. 
 
The activity shown by the extracts of C. angustum and P. illyricum before on 
microorganisms ATCC strains and after on clinical isolates multi-drug resistant, 
nominate some of the alkaloids they contain as potential compounds to treat, alone or in 
association with compounds multi-drug resistant, infections by pathogens to date harder 
to eliminate. As regards the extract of C. angustum was assumed like component 
responsible of the activity, the galanthindole. In future studies should be try to isolate 
this compound and test individually, in order to determine its real activity, and probably 
as occurs in this type of assays, to compare its activity with that of the total extract. Like 
occurred in fact in the bulbs extract of P. illyricum, the activity shown by the extract is 
lower than that shown by lycorine, purified alkaloid from P. illyricum extract. 
 
As regards the development of in vitro cell cultures, these plants of the Amaryllidaceae 
family, have proved refractoriness to the development of in vitro cultures, or rather, the 
only in vitro development to which lend themselves is that to form regenerated plants 
from tissues explants. Although this is not the desired result, as, a development of 
suspension cells would have led to a large quantities and  rapid production of secondary 
metabolites, the ultimate goal to preservation of plant species and the production of 
alkaloids, was not invalidated. For instance tests conducted on micropropagated plant 
extracts of L. nicaeense have shown that in vitro production of natural compounds, can  
equate that in nature, and can represent an excellent source of pharmacologically active 
compounds. 
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By concluding, the extracts obtained from plants of, C. angustum, P. illyricum and L. 
nicaeense, belonging to the Amaryllidaceae family, have been the source of molecules 
with high pharmacological potential, whose applicability covers various fields, like: 
neurodegenerative diseases, antineoplastic activity, anti-aging, and antimicrobial 
activity. The production of these compounds by means of plant cell cultures allows a 
higher and selective production, independent of the availability and the seasonality of 
the plant, not least allows the preservation of plant species. 
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